Development of Targeted, Polymeric Delivery Vehicles for Camptothesin and siRNA Via Boronic Acid-Diol Complexation by Han, Han
 Development of Targeted, Polymeric Delivery Vehicles for 
Camptothecin and siRNA  
via Boronic Acid-Diol Complexation 
 
 
 
 
Thesis by 
Han Han 
 
 
 
 
In Partial Fulfillment of the Requirements 
for the degree of 
Doctor of Philosophy 
 
 
California Institute of Technology 
Pasadena, California 
2013 
(Defended December 7, 2012) 
! ii!
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2013 
Han Han 
All Rights Reserved 
! iii!
Acknowledgments 
As a child, I have always wanted to know the reasons behind why and how things 
work. To this end, I have taken apart and broken many things, and wherever I went the 
path of destruction seemed to follow. I thank my parents for putting up with me during 
these years and for still always encouraging me to pursue and satisfy my curiosities. I am 
grateful that they have given me many siblings to grow up with, having a large family 
means that laughter and warmth are never in shortage.  
I would like to thank all the professors from the University of Melbourne who 
have taught me and have helped in developing me scientifically including Professors 
Michelle Gee, George Franks, Sandra Kentish and Andrea O’Connor. I am greatly 
indebted to Professor Dave Dunstan for mentoring me during my first research project 
and for giving me the freedom to ask questions and seek answers. It was this research 
experience that led to my desire to pursue graduate studies. Special thanks to Professor 
Peter Scales who has made the lectures especially enjoyable and has helped in guiding 
me on my career path.  
I would like to thank the staff at Caltech who has helped me throughout the years 
including Martha Hepworth, Kathy Bubash, Suresh Guptha and Steve Gould. To the 
professors who have taught me, including Professors John Brady, Zhen-Gang Wang, Bob 
Grubbs, Scott Virgil, Judith Campbell and Carl Parker – I thank you. I am indebted to 
Doctors David VanderVelde, Alasdair McDowall and Mona Shahgholi for training me on 
the usage of NMR, TEM, and mass spectroscopy, respectively, and for always being 
available when I needed assistance. I am grateful to Professor Jeremiah Johnson and 
Doctor Janek Szychowski for their invaluable discussions in organic synthesis. I would 
! iv!
like to thank Professors Dave Tirrell, Zhen-Gang Wang and Bob Grubbs for taking their 
time to be on my thesis committee.  
I appreciate everyone in the Davis group who has helped me and has made my 
time more enjoyable. I am grateful to Chris Alabi for teaching me lab work and for 
answering my endless questions. I am thankful to Jonathan Choi for helping me in getting 
started in the lab and for being a great friend. I am glad to have worked with Fanny 
Eriksen and thankful for the continued friendship. A big thanks to Leonard Medrano for 
assisting me with lab work whenever needed. I am thankful to Yasho Bhawe for helping 
me both in and outside the lab, and for being a great friend. I am grateful to Devin Wiley 
and Aaron Gale for always being willing to assist me with lab work. 
I would like to thank all the friends whom I have made while cycling. I am 
grateful for their patience in helping me in getting started in this sport and look back 
fondly on the adventures we have had.  
All that I have learnt and achieved in the past few years would not have been 
possible without my advisor, Professor Mark Davis. The reason I chose to come to 
Caltech was to work with Mark. I am especially appreciative of all the flexibility he has 
given me, the interesting discussions we have had and for the guidance he has provided. 
Mark’s mentoring style has helped me to grow and mature scientifically. I couldn’t have 
asked for more.   
 
 
 
 
! v!
Abstract 
Our research lab has developed polymer-based nanoparticle delivery systems for 
the anticancer drug, camptothecin (CPT), CRLX101; and for the small interfering RNA 
(siRNA), CALAA-01. CRLX101 has shown great success in both animal studies and 
clinical trials. However, it is incapable of achieving targeted delivery. CALAA-01 has 
demonstrated effectiveness in a phase I clinical trial. However, it suffers from its rapid in 
vivo clearance. To address the issues of targeting in the anticancer drug delivery system 
and the short circulation time in the siRNA delivery system, we have created a new 
delivery platform involving the use of boronic acid-diol complexation. This thesis is 
divided into two parts to discuss CPT delivery and siRNA delivery separately.  
In Part I, the targeted delivery of CPT via boronic acid-diol complexation is 
described. CPT was conjugated to a copolymer of mucic acid and PEG (MAP) and self-
assembled into MAP-CPT nanoparticles. The targeting agent, Herceptin antibody was 
attached to boronic acid (BA), this was then complexed with the diol-containing MAP to 
form a targeted nanoparticle carrying ca. 60 CPT, with a 40 nm diameter and a slightly 
negative surface charge. The attachment of a single Herceptin per nanoparticle was 
sufficient to enhance cellular uptake of nanoparticles into BT-474, a HER2 
overexpressing cell line by 70% compared to the non-targeted version. Nude mice 
bearing BT-474 xenograft tumors treated with targeted MAP-CPT nanoparticles resulted 
in all mice revealing complete tumor regression.  
In Part II, the boronic acid-diol complexation delivery platform is applied for the 
delivery of siRNA. First, the CALAA-01 delivery system for siRNA was further 
characterized and optimized. Then, a copolymer of mucic acid and dimethylsuberimidate 
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(MAD) was synthesized and used in condensing the anionic siRNA into nanoparticles. 
Nanoparticles were stabilized by placing a surface PEG layer through boronic acid-diol 
complexation. Targeting was achieved by conjugating the distal end of the BA-PEG with 
a targeting agent, Herceptin antibody. MAD/siRNA nanoparticles effectively entered 
cells and demonstrated low cellular toxicity. MAD/siRNA nanoparticles stabilized with 
nitroPBA-PEG resulted in a diameter of 130 nm with a slightly negative surface charge. 
Pharmacokinetic studies in mice demonstrated improved circulation compared to 
CALAA-01.  
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Introduction 
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Cancer is a leading cause of death worldwide. In the United States, one in two 
men and one in three women would develop cancer within their lifetimes. Recently, death 
due to cancer has surpassed heart diseases in Hispanic/Latino populations (1, 2). Current 
cancer treatments for solid tumors include surgical removal, radiation therapy and 
chemotherapy involving cytotoxic drugs. Chemotherapies are commonly administered 
especially in patients with metastasized cancers. However factors including rapid 
systemic clearance, multidrug resistance and nonspecific toxicity result in low efficacy 
and numerous side effects. To improve efficacy and minimize side effects, a delivery 
vehicle is desired to protect and transport the payload to the solid tumor site. One of the 
most promising approaches to achieve this is the targeted delivery of therapeutics via 
nanoscaled vehicles due to their ability to protect their payload and enhance its delivery 
to cancerous cells by passive and active targeting; and their ability to bypass multidrug 
resistance (3, 4).  
Solid tumors are characterized by irregular and leaky vasculature with 200 nm to 
600 nm pore sizes (5, 6) and impaired lymphatic drainage, these features result in the 
preferential accumulation of macromolecules in the tumor site in a process known as the 
enhanced permeability and retention (EPR) effect (7). To take advantage of this 
phenomenon and in the process achieve passive targeting, nanoparticles are designed to 
be between 10 and 100 nm in size. 10 nm is chosen as the lower size limit to avoid first 
pass kidney clearance (8), while 100 nm is set as the upper limit to minimize recognition 
and clearance by the mononuclear phagocyte system (MPS). Recently it has been shown 
that nanotherapeutics of ca. 100 nm are effective in highly permeable tumors such as 
Kaposi’s sarcoma (9) but not in poorly permeable tumors due to limited penetration. 
! 3!
Nanoparticles smaller than 50 nm is necessary for tumor penetration in poorly permeable 
tumors such as human pancreatic adenocarcinoma BxPC-3 (10). To take full advantage 
of the EPR effect, nanoparticles should circulate for a long period of time to allow for 
accumulation at the tumor site. Therefore, in addition to size considerations, 
nanoparticles with slightly negative surface charges are desired to evade the electrostatic 
interactions with blood components and to reduce the clearance by the MPS (11). As well, 
polyethylene glycol (PEG), a biocompatible polymer is often used as a ‘stealth’ layer on 
the surface of nanoparticles to shield against self-self interactions that lead to aggregation 
and to shield against self-non-self interactions such as opsonin adsorption that result in 
removal by the MPS (12, 13).  
Once the nanoparticles have reached the solid tumor site by the EPR effect, it is 
advantageous to actively target the nanoparticles to the cancerous cells for enhanced 
cellular uptake (14, 15). This can be achieved by functionalizing the surface of 
nanoparticles with ligands against over-expressed or specific receptors on tumor cell 
surfaces. Studies have shown that nanoparticles with and without targeting resulted in 
similar biodistribution and amount reaching tumor site (14, 16, 17).  However, the same 
studies found that targeted nanoparticles show significant tumor reduction efficacy 
compared to their non-targeted counterparts. This suggests that the targeted delivery of 
nanoparticles enhances cellular internalization of nanoparticles via receptor mediated 
endocytosis rather than by increasing the accumulation of the nanoparticles at the tumor 
site. 
 In the past years, our research lab has developed polymer-based nanoparticle 
delivery systems for the anticancer drug, camptothecin (CPT), named CRLX101 
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(formerly IT-101); and for the small interfering RNA (siRNA), named CALAA-01. The 
basis of these systems involves the use of β-cyclodextrin-containing polymers (CDP). IT-
101 is composed of CPT conjugated to CDP and is self-assembled into nanoparticles by 
hydrophobic interactions (18, 19). This drug delivery system has shown great success in 
both animal studies (20, 21) and clinical trials (22). However, it is incapable of achieving 
targeted delivery. We expect that with targeting, the efficacy of this type of delivery 
system would be enhanced. CALAA-01 is composed of anionic siRNA condensed by 
cationic CDP to form nanoparticles via electrostatic interactions (23, 24). This 
nanoparticle system is stabilized by the presence of a steric PEG layer on its surface. The 
attachment of PEG onto the nanoparticles is attained by the formation of inclusion 
complexes of adamantine (AD) with the cyclodextrins in the polymer via an adamantane 
PEG conjugate (AD-PEG). Targeting is achieved by attaching ligands, such as human 
transferrin protein on the AD-PEG conjugate to form AD-PEG-Transferrin. This siRNA 
delivery system has shown rapid clearance rate in in vivo imaging and in non-human 
primate plasma studies (25, 26).  This is likely due to the weak non-covalent interactions 
between the AD-PEG and the β-cyclodextrin in the stabilization process.  Nevertheless, 
this siRNA therapy route has recently been shown to be effective in human during a 
phase I clinical trial (24). Thus with a more stable and long circulating delivery system 
we expect to achieve better therapeutic efficacy by allowing more particles to reach the 
tumor site via the EPR effect. 
To address the issues of targeting in the anticancer drug delivery system and short 
circulation time in the siRNA delivery system, we have created a new targeted delivery 
platform involving the use of boronic acid-diol complexation (Scheme 1.1). 
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Boronic acids have been used in a variety of pharmaceutical agents such as in the 
FDA approved proteasome inhibitor, Bortezomib (27), in glucose sensing by the 
formation of boronic acid-diol complexes (28, 29), in boron neutron capture therapy 
(BNCT) for localized radiation therapy (30, 31) and in compounds to create drug delivery 
systems such as the recent complexation of boronic acids with diols to form cross-linked 
micelles (32, 33).  
We demonstrate a new assembly of targeted nanoparticles that employs boronic 
acid complexation with diols. That is, nanoparticles are assembled using polymers that 
have sugars in their backbone, e.g., mucic acid, to provide a repeating unit that contains 
vicinal diols. Nanoparticle targeting agents are conjugated with flexible spacing groups, 
e.g., polyethylene glycol (PEG), and terminated with a boronic acid. These targeting 
moieties are then assembled onto the surface of the nanoparticle via the reversible, 
covalent bonding between the boronic acid and the surface vicinal diols of the polymer. 
This complexation system can have numerous functionalities that allow for assembly 
with a wide variety of therapeutic and imaging agents (34).  
For the targeted delivery of anticancer drugs, for instance, the small hydrophobic 
drug CPT, the complexation between boronic acids on the targeting moiety and vicinal 
diols on the polymer can be used to form a targeted nanoparticle delivery system. 
Specifically, CPT is conjugated onto a biocompatible hydrophilic copolymer backbone of 
mucic acid and PEG (MAP). This conjugate, when placed in water can self-assemble into 
nanoparticles. The addition of the targeting agent of choice is achieved by exploiting the 
complexation between boronic acids in the targeting moiety and the mucic acid repeats in 
the polymer backbone (Scheme 1.1). This will be described in Part I of this thesis. 
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For the targeted delivery of siRNA, the same boronic acid-diol complexation 
platform can be exploited. A cationic biocompatible hydrophilic copolymer backbone of 
mucic acid and dimethylsuberimidate (MAD) is used to condense anionic siRNA into 
nanoparticles. PEG and targeting agent terminated with boronic acid are used for 
stabilization and targeting purposes respectively via the complexation of boronic acid 
with the mucic acid repeats in the polymer backbone (Scheme 1.1). This will be 
described in Part II of this thesis.  
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Scheme 1.1 Delivery platform involving boronic acid-diol complexation for the (I) 
targeted delivery of anticancer drug, camptothecin (CPT) and the (II) targeted delivery of 
small interfering RNA (siRNA). Abbreviations: CPT-gly, CPT with glycine linker; DMS, 
dimethylsuberimidate; MAP, mucic acid and PEG copolymer; MAD, mucic acid and 
dimethylsuberimidate copolymer; BA, boronic acid. 
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2.1 Abstract  
The delivery of therapeutics via nanoscaled vehicles for solid cancer treatment 
can be enhanced by the incorporation of targeting capability. In here, the reversible 
covalent complexation between boronic acids and diols is used to achieve targeting for 
the delivery of small hydrophobic drug camptothecin (CPT). CPT is conjugated to a 
biocompatible hydrophilic copolymer of mucic acid and PEG (MAP). This when placed 
in water, self-assembles into MAP-CPT nanoparticles. The targeting agent of choice, 
Herceptin antibody is attached to boronic acid. This boronic acid-containing targeting 
moiety then complexes with the diol-containing MAP to form a targeted MAP-CPT 
nanoparticle. MAP polymer lengths of 20 kDa (short), 65 kDa (medium) and 102 kDa 
(long) are synthesized. Upon conjugation of CPT, nanoparticle sizes of ca. 30 nm and 
slightly negative surface charges are observed for all. The addition of Herceptin targeting 
agent to medium MAP-CPT nanoparticles to form targeted MAP-CPT nanoparticles 
increases nanoparticle size to ca. 40 nm with a slightly negative surface charge.  
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2.2 Introduction 
  Nanoparticles are finding application for the delivery of a broad range of 
therapeutic and imaging agents, some of which are currently being investigated in human 
clinical trials (1, 2). When nanoparticles are employed for the delivery of therapeutics to 
solid cancers, they rely upon the enhanced permeability and retention (EPR) effect to 
accumulate in the tumors (3). After reaching the tumor site by the EPR effect, 
nanoparticles containing targeting agents that can engage cancer cell surface receptors are 
shown to achieve uptake into cancer cells in amounts exceeding those of non-targeted 
nanoparticles with similar size and surface charge (4-6). 
  Our research group has been involved in translating two polymer-based 
nanoparticles from the laboratory to the clinic.  The first, CRLX101 (previously known 
as IT-101) is a ca. 30 nm, non-targeted nanoparticle composed of a cyclodextrin-polymer 
conjugate of anticancer drug camptothecin (CPT) (7). The second, CALAA-01, is a ca. 
70 nm human protein transferrin targeted nanoparticle comprised of cyclodextrin-
polymer and siRNA (8, 9). The method of assembling the targeting moiety onto the 
CALAA-01 nanoparticle involves the formation of inclusion complexes of adamantane 
with the cyclodextrins in the polymer (8). Since the method of assembling CRLX101 
utilizes inclusion complex formation between the cyclodextrins in the polymer with the 
conjugated CPT, the targeting methodology employed with CALAA-01 is not amenable 
for CRLX101. Because of this issue and others that were encountered as these 
nanoparticles were translated to the clinic, we have been exploring new ways of 
assembling targeted nanoparticles that could carry any type of payload. Here, we describe 
a methodology to create targeted nanoparticles that involves the use of boronic acid-diol 
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complexes. 
  Boronic acids have been used: (i) in a variety of pharmaceutical agents, (ii) in 
creating devices to sense sugars and (iii) in compounds to create drug delivery materials 
and devices (10).  For example, the complexation of boronic acids with diols has recently 
been employed to assemble cross-linked micelles (11, 12). Here, we demonstrate a new 
assembly of targeted nanoparticles that employs boronic acid complexation with diols. 
That is, nanoparticles are assembled using polymers that have sugars in their backbone, 
e.g., mucic acid, to provide a repeating unit that contains vicinal diols. Nanoparticle 
targeting agents are conjugated with flexible spacing groups, e.g., polyethylene glycol 
(PEG), and terminated with a boronic acid. These targeting moieties are then assembled 
onto the surface of the nanoparticle via the reversible, covalent bonding between the 
boronic acid and the surface vicinal diols of the polymer (Scheme 2.1). This 
complexation system can have numerous functionalities that allow for assembly with a 
wide variety of therapeutic and imaging agents (13). For example, small hydrophobic 
drug molecules like CPT can be conjugated to the polymer backbone and self-assembled 
into nanoparticles.  
In this chapter, an antibody (Herceptin) targeted, polymer-based nanoparticle 
system for the delivery of CPT that utilizes the complexation of boronic acids on the 
antibody targeting moiety and vicinal diols on the polymer for assembly of the targeted 
nanoparticle was synthesized. CPT was conjugated onto a biocompatible hydrophilic 
copolymer backbone of mucic acid and PEG (MAP). This conjugate, when placed in 
water self-assembled into nanoparticles. Addition of the antibody targeting agent was 
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achieved by exploiting the complexation between boronic acids in the targeting moiety 
and the mucic acid repeats in the polymer (Scheme 2.1). 
 
 
Scheme 2.1 Targeted MAP-CPT nanoparticle delivery system assembly. MAP, 
copolymer of mucic acid and polyethylene glycol; CPT, camptothecin; BA, boronic acid.   
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2.3 Experimental  
2.3.1 General 
All commercially purchased reagents and solvents including anhydrous and 
HPLC grade were used without further purification. Boc-L-aspartic acid 4-benzyl 1-(N-
hydroxysuccinimide) ester (Boc-Asp(OBzl)-OSu) was purchased from Bachem 
(Bubendorf, Switzerland). Disuccinimidyl propionate poly(ethylene glycol) (diSPA-PEG, 
MW 3400) was purchased from Sunbio (South Korea). Camptothecin was obtained from 
Boehringer Ingelheim (Ingelheim, Germany). 3-carboxylphenylboronic acid and 3-
carboxy 5-nitrophenylboronic acid were purchased from Alfa Aesar (Ward Hill, MA). 
Amine polyethylene glycol carboxylic acid (NH2-PEG-CO2H, MW 5000) was purchased 
from JenKem Technology USA (Allen, TX). Herceptin® (Trastuzumab) was obtained 
from Dr. Y. Yen at the City of Hope (Duarte, CA). All other reagents were purchased 
from Sigma (St Louis, MO).  
1H, 13C and 19F NMR spectra were recorded on either a 500 MHz or 600 MHz 
spectrometer (Inova, Varian). Mass spectrometry was carried out using a LCQ ion trap 
mass spectrometer (Finnigan, Thermo) by direct infusion electrospray ionization or 
MALDI-TOF mass spectrometer (Voyager DETM-PRO, Applied Biosystems).  
Absorbance and fluorescence measurements were taken on a microplate reader 
(Infinite 200, Tecan). 
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2.3.2 Preparation and Characterization of MAP-CPT Nanoparticles  
1. Mucic acid dimethyl ester 
120 ml of methanol and 0.4 ml of concentrated sulfuric acid were added to 5 g 
(22.8 mmol) of mucic acid.  This mixture was refluxed at 85 oC overnight under constant 
stirring.  Solids were filtered, washed with methanol, recrystallized and dried under 
vacuum overnight to yield 8 g (71%) of mucic acid dimethyl ester. 1H NMR ((CD3)2SO) 
δ 4.88-4.91 (d, 2H), 4.78-4.81 (m, 2H), 4.28-4.31 (d, 2H), 3.77-3.78 (d, 2H), 3.63 (s, 6H).  
ESI/MS (m/z): 261.0 [M+Na]+. 
2. Protected mucic acid diamine  
60 ml of methanol, 5.25 g (32.7 mmol) of N-Boc-ethylenediamine and 5.7 ml 
(32.7 mmol) of N, N-diisopropylethylamine (DIPEA) were added to 3 g (12.6 mmol) of 
mucic acid dimethyl ester. This reaction mixture was refluxed at 85 oC overnight under 
constant stirring. Solids were filtered, washed with methanol, recrystallized and dried 
under vacuum to give 4.65 g (75%) of product.   1H NMR ((CD3)2SO) δ 7.72 (t, 2H), 6.82 
(t, 2H), 5.13-5.15 (d, 2H), 4.35-4.38 (d, 2H), 4.08-4.11 (d, 2H), 3.78-3.80 (d, 2H), 2.95-
3.15 (m, 8H), 1.36 (s, 18).  ESI/MS (m/z): 517.1 [M+Na]+. 
3. Mucic acid diamine 
8 g (16.2 mmol) of protected mucic acid diamine was transferred to a flask 
containing 3 N HCl in methanol (160 ml) and reacted for 6 h at room temperature under 
constant stirring.  Precipitate was filtered, washed with methanol and vacuum dried 
overnight to yield 5.69 g (96%) of mucic acid diamine.   1H NMR ((CD3)2SO) δ 7.93-
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7.99 (m, 8H), 5.31-5.34 (d, 2H), 4.57 (d, 2H), 4.10-4.17 (d, 2H), 3.82 (d, 2H), 3.32-3.38 
(m, 4H), 2.82-2.86 (m, 4H).  ESI/MS (m/z): 295.1 [M]+. 
4. Mucic acid di(Asp(OBzl)-Boc) 
9.27 g (22.1 mmol) of Boc-Asp(OBzl)-OSu in 75 ml of acetonitrile and 2.88 ml 
(35.8 mmol) of pyridine was added to 2.7 g (7.35 mmol) of mucic acid diamine dissolved 
in 45 ml water. This reaction mixture was refluxed at 60 oC overnight under constant 
stirring.  Acetonitrile was removed by rotavap and resulting precipitate was recrystallized 
from hot water and dried under vacuum to yield 2.03 g (31%) mucic acid di(Asp(OBzl)-
Boc). 1H NMR ((CD3)2SO) δ 7.93 (t, 2H), 7.75 (t, 2H), 7.29-7.35 (m, 10H), 7.05 (d, 2H), 
5.11 (t, 2H), 5.06 (s, 4H), 4.34-4.39 (d, 2H), 4.25-4.30 (d, 2H), 4.10-4.12 (d, 2H), 3.77-
3.79 (d, 2H), 3.11-3.15 (m, 8H), 2.53-2.78 (m, 4H), 1.36 (s, 18H). ESI/MS (m/z): 927.4 
[M+Na]+. 
5. Mucic acid di(Asp(OBzl)-amine) 
6 ml (80.8 mmol) of trifluoroacetic acid was slowly added to 2 g (2.21 mmol) of 
mucic acid di(Asp(OBzl)-Boc) dissolved in 18 ml of dichloromethane on an ice bath. The 
reaction was allowed to proceed for 4 h in ice bath. Solvent was removed, precipitate 
recrystallized with tetrahydrofuran and dried on vacuum to yield 1.74 g (84%) of product. 
1H NMR ((CD3)2SO) δ 8.46 (t, 2H), 8.21 (s, 6H), 7.79 (t, 2H), 7.32-7.38 (m, 10H), 5.19 (t, 
2H), 5.14 (s, 4H), 4.41 (s, 2H), 4.11-4.14 (d, 2H), 4.02-4.06 (d, 2H), 3.81 (s, 2H), 3.11-
3.23 (m, 8H), 2.79-3.02 (m, 4H). ESI/MS (m/z): 705.4 [M]+. 
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6. Mucic acid di(Asp-amine)  
511 mg (13.5 mmol) of 20 wt% palladium hydroxide on carbon was transferred to 
1.26 g (1.35 mmol) of mucic acid di(Asp(OBzl)-amine) dissolved in 50 ml of methanol. 
Reaction vessel was sealed and vented with argon. Hydrogen gas was added via double-
layered balloon for 24 h. Catalyst was filtered away, solvent removed and precipitate 
dried on vacuum. This was then reconstituted in water, filtered with a 0.2 µm membrane 
filter (Acrodisc) and lyophilized to yield 711 mg (70%) of product. 1H NMR ((CD3)2SO) 
δ 8.44 (t, 2H), 8.19 (broad, 6H), 7.80 (t, 2H), 5.22 (t, 2H), 4.48 (s, 2H), 4.12 (s, 2H), 
3.94-3.99 (m, 2H), 3.80 (s, 2H), 3.11-3.23 (m, 8H), 2.70-2.85 (m, 4H). ESI/MS (m/z): 
525.2 [M]+. 
7. MAP (Mucic Acid containing Polymer) 
111 mg of mucic acid di(Asp-amine) (0.15 mM) and 500 mg of diSPA-
PEG3.4kDa (0.15 mM) were dried under vacuum for 6 h. 3.5 ml of anhydrous dimethyl 
sulfoxide was added under argon to dissolve the reactants. 82 µl (0.47 mM) of anhydrous 
DIPEA was then added under argon and reaction was allowed to proceed for 40 h at room 
temperature under constant stirring. Reaction mixture was then dialyzed with 10 kDa 
MWCO membrane filter device (Amicon) 4 times, filtered through a 0.2 µm membrane 
filter (Acrodisc) and lyophilized to yield 466 mg (81%) MAP. GPC (for medium MAP): 
Mn = 55.5 kDa, Mw = 75.3 kDa, Mw/Mn = 1.36.  1H NMR ((CD3)2SO, for medium 
MAP) δ 8.07 (d, 1H), 8.04 (d, 1H), 7.83 (t, 1H), 7.77 (t, 1H), 7.69 (t, 2H), 4.43 (td, 2H), 
4.10 (d, 2H), 3.75 (ddt, 2H), 3.55 (t, 4.3H), 3.42-3.52 (PEG peak, 330H), 3.05-3.16 (m, 
8H), 2.90 (broad, 0.6H), 2.39-2.53 (m, 4H), 2.34 (t, 4.3H), 1.12 (m, 6H). 13C NMR (D2O, 
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for medium MAP) δ 175.7, 174.9, 174.0, 172.9, 66.5, 69.6, 70.6, 54.3, 50.6, 42.5, 38.8, 
38.3, 36.5, 35.7, 17.7, 16.2, 12.1. 
8. Absolute molecular weight determination of MAP 
The absolute determination of molecular weights does not require standards for 
calibration. This was determined on a GPC system equipped with an Agilent pump, 
degasser and autosampler, double gel permeation columns (PL aquagel-OH 40 8 µm 300 
x 7.5 mm, Polymer Laboratory) in series connected to a multi-angle laser light scattering 
(MALS) detector (DAWN HELEOS, Wyatt) and a refractive index (RI) detector (Optilab 
rEX, Wyatt). PBS (1x, 0.02 w/w% sodium azide, pH 7.4) was used as the eluent at a flow 
rate of 0.7 ml/min. Specific refractive increment, dn/dc was measured by batch injection 
of various concentrations of MAP dissolved in PBS into Optilab rEX at 0.2 ml/min. 
9. Molecular weight control of MAP 
Molecular weight of MAP was controlled by the amount of tertiary base, N, N-
diisopropylethylamine (DIPEA) added to the reaction. After dissolving equal molar ratios 
of mucic acid di(Asp-amine) and diSPA-PEG3.4kDa in anhydrous dimethyl sulfoxide, 
different equivalents (1.1, 1.6 and 2) of anhydrous DIPEA to amine groups on mucic acid 
di(Asp-amine) were added. The reactions were then carried out and the polymers 
processed as per the methods described in section 7 (vide supra). Three polymers of 
differing molecular weights were prepared and denoted as short, medium and long.  
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10. 20-O-glycinylcamptothecin trifluoroacetic acid salt (CPT-gly.TFA)   
20-O-glycinylcamptothecin trifluoroacetic acid salt (CPT-gly.TFA) was 
synthesized as previously reported (14). 
11. MAP-CPT conjugate 
403 mg (0.22 mM on -CO2H basis) of MAP was dissolved in 20 ml of anhydrous 
dimethyl sulfoxide. To this was added 167 mg (0.87 mM) of EDC and 75 mg (0.65 mM) 
of NHS dissolved in 6 ml of anhydrous dimethyl sulfoxide, 340 mg (0.65 mM) of 20-O-
glycinylcamptothecin trifluoroacetic acid salt (CPT-gly.TFA) dissolved in 6 ml of 
anhydrous dimethyl sulfoxide and 114 µl (0.65 mM) of anhydrous DIPEA under argon. 
After overnight reaction under constant stirring, the reaction mixture was dialyzed against 
dimethyl sulfoxide 3 times and water 2 times using 10 kDa MWCO membrane 
(Spectra/Por 7). Any insoluble material was removed by centrifugation and supernatant 
was filtered with a 0.2 µm filter (Acrodisc). A portion of this clear yellow solution was 
lyophilized for yield determination and percent CPT conjugation analysis. The remaining 
was formulated into 0.9 w/v% saline and stored at -20 oC. 
12. CPT content in MAP-CPT  
Weight percent of CPT in MAP-CPT was determined by the intrinsic 
fluorescence of CPT. MAP-CPT was dissolved in dimethyl sulfoxide at 10 mg/ml. This 
was diluted into 0.1 mg/ml with 1 N NaOH and incubated overnight. Fluorescence was 
measured at excitation 370 nm, emission 440 nm, and compared to that of known 
concentrations of CPT. 
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13. Nanoparticle composition  
Nanoparticle compositions were analyzed as per the methods described in section 
8 (vide supra) except gel permeation columns were bypassed. Dn/dc value of MAP-CPT 
nanoparticles was measured by batch injection of various concentrations of MAP-CPT 
nanoparticles dissolved in PBS into Optilab rEX at 0.2 ml/min. This allowed for the 
molecular weight determination of MAP-CPT nanoparticles. The number of MAP-CPT 
conjugates per nanoparticle was then calculated from this data. 
14. Nanoparticle size and surface charge  
Particle size and zeta potential measurements were determined by dynamic light 
scattering (DLS) using a ZetaPALS instrument (Brookhaven Instruments, Holtsville, NY). 
Effective hydrodynamic diameter was recorded and averaged from 10 runs at 1 min each. 
Zeta potential measurements were collected for three sets of 10 runs at a target residual of 
0.012, and the results were averaged.  
15. Nanoparticle morphology 
Nanoparticle morphology was visualized by cryo-electron microscopy (cryo-EM). 
Glow discharged Quantifoil holey carbon grid (SPI Supplies) was loaded into an 
automated climate-controlled plunge-freezer (Vitrobot, FEI) and 3 µl of sample was 
applied. Grid was blotted, drained, plunged into liquid ethane, transferred and stored in 
liquid nitrogen. Samples were visualized under cryogenic temperatures with transmission 
electron microscope (Tecnai T12, FEI) equipped with a cryo-specimen holder. 
Acceleration voltage was set at 120 kV. 
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2.3.3 Preparation and Characterization of Targeted MAP-CPT Nanoparticles 
1. PBA-PEG-CO2H (3-amide-PEG5kDa-carboxylic acid phenylboronic acid) 
To 200 mg (1.21 mM) of 3-carboxyphenylboronic acid dissolved in 5 ml of 
anhydrous tetrahydrofuran was added 18.7 µl (0.24 mM) of anhydrous 
dimethylformamide under argon. This reaction vessel was transferred into an ice bath and 
195 µl (2.89 mM) of oxalyl chloride was slowly added under argon. Reaction was 
allowed to proceed under vent and constant stirring for 2 h at room temperature. Solvent 
and excess reagent were removed under vacuum. 37 mg (0.2 mM) of this dried acyl 
chloride compound was dissolved in 15 ml of anhydrous dichloromethane under argon. 
To this was added 500 mg (0.1 mM) of NH2-PEG5kDa-CO2H and 52 µl (0.3 mM) of dry 
DIPEA under argon. After overnight reaction under constant stirring, solvent was 
removed under vacuum and the dried product was reconstituted in 0.5 N HCl. This 
solution was passed through a 0.2 µm filter (Acrodisc) and dialyzed against water with a 
3 kDa MWCO membrane filter device (Amicon) until constant pH was attained. The 
supernatant was then filtered with a 0.2 µm filter (Acrodisc) and lyophilized to yield 377 
mg (73%) of PBA-PEG-CO2H. 1H NMR ((CD3)2SO) δ 12.52 (s, 1H), 8.39 (t, 1H), 8.22 (s, 
1H), 8.14 (s, 2H), 7.88 (d, 1H), 7.82 (d, 1H), 7.39 (t, 1H), 3.99 (s, 2H),  3.35-3.62 (PEG 
peak). MALDI-TOF (m/z): 5600 g/mol (NH2-PEG5kDa-CO2H, 5400 g/mol). 
2. nitroPBA-PEG-CO2H (3-amide-PEG5kDa-carboxylic acid, 5-nitrophenylboronic 
acid)  
Synthesis of nitroPBA-PEG-CO2H was performed in the same way as for PBA-
PEG-CO2H except the starting material was 3-carboxy 5-nitrophenylboronic acid. The 
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reaction yielded 393 mg (76%) of nitroPBA-PEG-CO2H. 1H NMR ((CD3)2SO) δ 12.52 (s, 
1H), 8.89 (t, 1H), 8.72 (s, 1H), 8.68 (s, 1H), 8.64 (s, 1H), 8.61 (s, 2H), 3.99 (s, 2H),  3.35-
3.62 (PEG peak). MALDI-TOF (m/z): 5600 g/mol (NH2-PEG5kDa-CO2H, 5400 g/mol). 
3. pKa determination for PBA 
pKa of PBA was found by measuring the change in absorbance of PBA as it 
converted from trigonal (in low pH) to tetrahedral (in high pH) conformation. To a 
solution of 10-3 M PBA in 0.1 M PBS, pH 7.4 was titrated 1 N NaOH. pH was recorded 
and corresponding samples were removed for absorbance measurements at 268 nm. 
4. Binding constant determination between PBA and MAP 
A three component competitive assay involving fluorescent dye Alizarin Red S, 
PBA and MAP (diol-containing) was used to determine the binding constant between 
PBA and MAP. This technique was developed by Springsteen and Wang (15). Briefly, 
the association constant Keq1 for Alizarin Red S-PBA complex was determined by 
changes in fluorescence as PBA was titrated into Alizarin Red S. MAP was then titrated 
into a solution containing Alizarin Red S and PBA. The addition of the MAP perturbed 
the first equilibrium due to MAP competing with Alizarin Red S for binding to PBA. 
Changes in fluorescence were measured and the association constant Keq between PBA 
and MAP was then determined. Measurements were performed in 0.1 M PBS at pH 7.4. 
5. Herceptin-PEG-nitroPBA (Herceptin-PEG5kDa-5-nitrophenylboronic acid) 
36 mg (6.4 µM) of nitroPBA-PEG-CO2H, 12.3 mg (64 µM) of EDC and 11.1 mg 
(96 µM) of NHS were dissolved in 2.4 ml of 0.1 M MES buffer, pH 6.0. This mixture 
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was reacted for 15 min on a rotating shaker at room temperature. Excess reactants were 
dialyzed away with 3 kDa MWCO membrane filter device (Amicon). This activated 
carboxylic acid PEG compound was added to 20 mg (0.14 mM) of Herceptin in 0.1 M 
PBS, pH 7.2. Reaction was carried out on a rotating shaker at room temperature for 2 h 
and then dialyzed 4 times with 50 kDa MWCO membrane filter device (Amicon) against 
1x PBS at pH 7.4. MALDI-TOF: average conjugation of 1 to 2 nitroPBA-PEG per 
antibody.  
6. Formulation of targeted MAP-CPT nanoparticles 
Herceptin-PEG-nitroPBA was added to the medium MAP-CPT nanoparticles to 
form targeted MAP-CPT nanoparticles at a ratio of one Herceptin per nanoparticle in 1x 
PBS, pH 7.4. 
7. Particle size, surface charge and morphology 
The methods used for the targeted nanoparticle were the same as for the non-
targeted nanoparticles as described in Preparation and Characterization of MAP-CPT 
Nanoparticles sections 14 and 15 (vide supra).  
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2.4 Results and Discussion 
2.4.1 Preparation and Characterization of MAP-CPT Nanoparticles  
 
 
Scheme 2.2 Synthesis of MAP-CPT nanoparticles.  
 
The synthesis methodology of the MAP-CPT conjugate and its assembly into 
MAP-CPT nanoparticles is outlined in Scheme 2.2.  Mucic acid was modified to contain 
both amino and carboxyl groups to allow for polymerization with PEG (amine group) and 
for conjugation of CPT (carboxyl group), respectively. It was observed via 19F NMR that 
the mucic acid di(Asp-amine) formed was the trifluoroacetic acid salt by comparing 
against standard (2-(trifluoromethyl)acetophenone). Therefore, for the polymerization 
reaction between mucic acid di(Asp-amine) and diSPA-PEG to proceed, a base was 
required for the deprotonation of -NH3+ group into the reactive -NH2 form. Here, tertiary 
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base N, N-diisopropylethylamine (DIPEA) was used. Figure 2.1 shows representative 
NMR data for the MAP polymers. The polymer end groups were determined to be -PEG-
CO2H by 1H NMR comparison of PEG and mucic acid di(Asp-amine) peak integrals. The 
molecular weight of MAP can be controlled by the amount of DIPEA added per NH3+ 
group on mucic acid di(Asp-amine) (Table 2.1). As the amount of DIPEA was increased, 
an increase in viscosity of the reaction mixture was observed. Three polymers were 
prepared and their properties are listed in Table 2.1.  
 
 
Figure 2.1 1H and 13C NMR spectra of medium MAP (A) 1H NMR in DMSO-d6. (B) 13C 
NMR in D2O. 
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Table 2.1 Characterization of MAP, MAP-CPT conjugate and MAP-CPT nanoparticles. 
aEquivalent amount of N, N-diisopropylethylamine (DIPEA) added per amine group in 
mucic acid di(Asp-amine). bMW, molecular weight determined as (Mw+Mn)/2; Mw, 
weight average molecular weight; Mn, number average molecular weight. cPolydispersity 
determined as Mw/Mn. 
 
It is noted that extra peaks were observed in 1H and 13C NMR spectra for MAP. 
This was identified as N-diisopropylethylamine (DIPEA) (Figure 2.2) and had a weight 
contribution of 1%. DIPEA was used in the synthesis of MAP and some residue likely 
remained after the dialysis process. This is largely due to DIPEA having a low solubility 
in water. Thus, in future synthesis, to remove the residue DIPEA, additional dialysis in 
DMSO is recommended. 
The absolute molecular weights of different lengths MAP were measured using 
multi-angle laser light scattering (MALS) and refractive index (RI) detections. A 
refractive index increment (dn/dc) value of 0.134 ml/g was found for the medium MAP. 
This dn/dc value along with MALS and RI data were used to determine the number 
Short Medium Long 
MAP 
Base added (equivalent)a 1.1 1.6 2 
MWb (kDa) 20  65  102 
Polydispersityc 1.22 1.36 1.13 
# repeat units (n) 5-7 15-21 25-30 
MAP-CPT 
conjugate 
MWb (kDa) 22  75  114  
wt % CPT conjugated 9.8 12.7 10.1 
MAP-CPT 
nanoparticle 
# conjugates/particle 2-3 2-3 2-3 
# CPT/particle ~14 ~60 ~72 
particle size (nm) ~30  ~30 ~30  
zeta potential (mV) -1.3+/-0.6 -0.5+/-0.5 -0.8+/-0.5 
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average molecular weight (Mn), weight average molecular weight (Mw) and 
polydispersity (Mw/Mn) of MAP (Table 2.1).  
 
 
Figure 2.2 Identification of extra peaks in NMR spectra of medium MAP (A) 1H NMR in 
DMSO-d6. (B) Addition of N-diisopropylethylamine (DIPEA). (C) Addition of more 
DIPEA. Arrows indicate the contaminate DIPEA peaks.  
 
CPT modified at 20-OH position has been reported to show significant reduction 
in deactivation caused by ring opening of the lactone (16). We therefore used CPT 
modified at this site with a glycine linker, CPT-gly, as was done previously with IT-101 
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(14). The CPT-gly was conjugated onto MAP to form MAP-CPT conjugate by standard 
EDC coupling technique (Scheme 2.1). The amount of CPT conjugated onto the three 
MAP polymers is reported in Table 2.1.  
Upon addition of water, the MAP-CPT conjugates self-assemble into 
nanoparticles since CPT is very soluble in dimethyl sulfoxide but not soluble to any 
significant amount in water. To determine the number of MAP-CPT conjugates per 
MAP-CPT nanoparticle. Dn/dc values of the MAP-CPT nanoparticles were found and the 
nanoparticles were characterized by MALS and RI detection. From these data, the 
molecular weight of each MAP-CPT nanoparticle was determined. Since the molecular 
weights of the MAP-CPT conjugates were known, the MAP-CPT nanoparticles were 
found to be composed of 2 to 3 MAP-CPT conjugates.  
MAP-CPT nanoparticles have an average particle size of ca. 30 nm (by DLS 
measurements) and a slightly negative surface charge (by Zeta Potential measurements). 
The negative surface charge is presumably due to the presence of unconjugated 
carboxylic acid groups on the MAP backbone. Cryo-EM was used to visualize the 
medium MAP-CPT nanoparticles in their native environment. Spherical nanoparticles 
with a narrow size range of 20-40 nm are observed (Figure 2.3).  
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Figure 2.3 Cryo-EM images of medium MAP-CPT nanoparticles. 
 
2.4.2 Preparation and Characterization of Targeted MAP-CPT Nanoparticles 
To prepare a targeted nanoparticle, the covalent, reversible binding property 
between boronic acids and MAP (diol-containing) was used. The binding constant 
between phenylboronic acid (PBA) and MAP is low at ca. 20 M-1. To increase the 
binding constant, PBAs with electron withdrawing groups on the phenyl ring were 
employed to increase the acidity of the boron atom and thus elevate the binding constant 
with MAP. Commercially available 3-carboxyPBA and 3-carboxy 5-nitroPBA were 
converted into acyl chlorides using oxalyl chloride (Scheme 2.3). These acyl chloride 
species were then reacted with NH2-PEG-CO2H to form PBA-PEG-CO2H and nitroPBA-
PEG-CO2H respectively (Scheme 2.3). The addition of bases DMF and DIPEA were 
required for the synthesis reactions to proceed. However, the presence of these bases 
resulted in tetrahedral adduct formations with acidic PBA. To remove these adducts, 
work up in 0.5 N HCl with subsequent equilibration to neutral pH by dialysis against 
water was carried out. 
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Scheme 2.3 Synthesis of PBA-PEG-CO2H and nitroPBA-PEG-CO2H.  
 
pKa values of the modified PBAs were determined by absorbance changes due to 
conformational change of PBA from trigonal to tetrahedral form as pH increased (Table 
2.3). PBA with electron withdrawing groups resulted in lower pKa’s, with nitroPBA-
PEG-CO2H having the lowest pKa of 6.8. Thus, at physiological pH, most of the PBA 
was present in the reactive anionic tetrahedral form. Binding constants between PBA and 
MAP were found by competitive binding with Alizarin Red S in 0.1 M PBS, pH 7.4. 
Because of the low pKa value and high binding constant with MAP observed for 
nitroPBA-PEG-CO2H, it was chosen as the linker between Herceptin and MAP-CPT 
nanoparticles.  
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Table 2.2 pKa values and binding constants of different PBAs (phenylboronic acids) 
with MAP.  
 
The conjugation reaction between Herceptin and nitroPBA-PEG-CO2H proceeded 
via EDC coupling (Scheme 2.4). An average of 1 to 2 PEGs were attached per Herceptin 
antibody. 
 
Scheme 2.4 Synthesis of Herceptin-PEG-nitroPBA.  
 
An average size of ca. 40 nm was observed for targeted MAP-CPT nanoparticles 
by DLS and cryo-EM (Table 2.2 and Figure 2.4). This increase in ca. 10 nm from the 
non-targeted nanoparticle suggests the attachment of ca. one Herceptin per nanoparticle. 
Indeed, from cryo-EM images, the targeted nanoparticles were not spherical but appeared 
to have protrusions indicating the attachment of antibodies. The surface charge of 
targeted MAP-CPT nanoparticles was slightly higher than MAP-CPT nanoparticles due 
to the presence of a positively charged Herceptin at pH 7.4 (pI of Herceptin, 9.2 (17)). 
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Table 2.3 Characterization of targeted MAP-CPT nanoparticles. 
 
    
Figure 2.4 Cryo-EM images of targeted MAP-CPT nanoparticles. 
 
 
 
 
 
 
 
Targeted 
MAP-CPT 
nanoparticle 
MAP  medium  
# CPT/particle ~60 
# Herceptin/particle 1 
particle size (nm) ~40 
zeta potential (mV) -0.4+/-0.6 
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2.5 Conclusions  
An example for the use of boronic acid-diol complexation in the targeted delivery 
of anticancer drugs via nanoscaled vehicles was presented. Targeted MAP-CPT 
nanoparticle delivery system for the small hydrophobic drug, CPT, was synthesized and 
characterized. It was composed of a biocompatible copolymer of mucic acid and PEG 
(MAP) enveloping the cytotoxic drug CPT. Targeting was achieved by attaching boronic 
acid to the targeting moiety of choice, in this case Herceptin antibody, and the subsequent 
complexation via boronic acid-diol formation with the mucic acid repeats in the MAP 
polymer.  
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Chapter III 
In Vitro Characterization of Targeted MAP-CPT  
Delivery System 
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3.1 Abstract  
The synthesis of targeted MAP-CPT delivery system was described in chapter II. 
In here, in vitro studies are conducted to understand the system and as a stepping-stone 
leading to in vivo studies. Cellular uptake of nanoparticles into BT-474, a HER2 
(Herceptin is antibody to this receptor) overexpressing cell line is enhanced by 70% 
compared to non-targeted version by the incorporation of a single Herceptin antibody 
targeting agent per nanoparticle. The main mechanisms of CPT release from MAP-CPT 
nanoparticles are found by in vitro release studies to be hydrolysis and nanoparticle 
disruption by the presence of fat. Cytotoxicity studies conducted in HER2 overexpressing 
breast cancer cells lines indicate lower IC50 values when treated with the Herceptin 
targeted nanoparticles compared to that treated with the non-targeted version; while the 
IC50 values for the HER2 negative cells lines are unaffected by the addition of the 
Herceptin targeting agent. 
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3.2 Introduction 
  One main objective for the use of targeted delivery of therapeutics is to reduce the 
proportion of therapeutics reaching the healthy tissues compared to the diseased tissues, 
such as solid tumors. This can be achieved by passive targeting. Macromolecules such as 
nanoparticles have an intrinsic ability to passively target solid tumors by preferentially 
accumulating in this site. This is because solid tumors are characterized by irregular and 
leaky vasculature with 200 nm to 600 nm pore sizes (1, 2) compared to normal 
vasculature which has pore sizes of 1 to 2 nm. This combined with the impaired 
lymphatic drainage in the solid tumor vasculature result in the enhanced accumulation of 
macromolecules in the tumor site. This process is known as the enhanced permeability 
and retention (EPR) effect (3).  
  Another objective for the use of targeted delivery of therapeutics is to increase the 
amount of cellular uptake of the therapeutics into the desired cells, in this case, solid 
tumor cells. This is often achieved by active targeting whereby targeting agents such as 
antibodies, antibody fragments and peptides are used to engage over-expressed or 
specific receptors on the cell surfaces for receptor mediated endocytosis. Recent studies 
show that nanoparticles with and without targeting demonstrate similar biodistribution 
and amount reaching the tumor site (4-6).  Yet the targeted nanoparticles show greater 
tumor reduction efficacy compared to the non-targeted versions. This led to the deduction 
that active targeting via targeting agents on the surface of nanoparticles enhances cellular 
uptake of nanoparticles by receptor mediated endocytosis. 
 The effect of using targeting in the delivery of therapeutics via nanoparticles can 
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be examined by in vitro studies by comparing the cellular uptake of targeted versus non-
targeted nanoparticles (7, 8).  In here, the HER2 overexpressing breast cancer cell line, 
BT-474 is used to see the effect of targeting on MAP-CPT nanoparticles as well as to 
determine the optimal amount of the targeting agent, Herceptin, that is required to 
achieve a higher uptake of nanoparticles compared to the non-targeted version. 
Competing free Herceptin, and a HER2 negative cell line (MCF-7), are used to determine 
the specificity of Herceptin targeting. 
  Cytotoxicity studies of targeted versus non-targeted nanoparticles in cell lines 
with different expressions of the targeted receptor can also be used to examine the effect 
of targeting. As well, it is used to determine the toxicity of the components in the delivery 
system on cells. It is expected that the carrier polymer, MAP and the boronic acid PEG 
linker between the MAP-CPT nanoparticles and the targeting agent, Herceptin, to show 
negative or minimal cellular toxicity. In here, four breast cancer cell lines, BT-474, 
SKBR-3, MCF-7 and MDA-MB-231 with different expressions of HER2 receptors are 
used.  
  In vitro release studies are employed to understand the mechanisms of release of 
therapeutics from its carrier and can be used as a predictor for its in vivo behavior. For 
IT-101, a nanoparticle composed of cyclodextrin-containing polymer conjugate of CPT, 
it was found that the mechanisms of release of CPT are hydrolysis and enzyme induced 
release (9). In here, a comprehensive examination of the release of CPT from the MAP-
CPT nanoparticles in various media and conditions are taken in an attempt to thoroughly 
understand its release mechanisms. 
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 3.3 Experimental  
3.3.1 General 
All commercially purchased reagents and solvents including anhydrous and 
HPLC grade were used without further purification. BT-474, MCF-7, SKBR-3 and 
MDA-MB-231 breast cancer cell lines were purchased from American Type Culture 
Collection (Manassas, VA). Female BALB/c mice were purchased from Jackson 
Laboratory (Bar Harbor, ME). Mice plasma was processed from fresh blood collected 
from female BALB/c mice. All other reagents were purchased from Sigma (St Louis, 
MO).  
Concentrations of unconjugated CPT and polymer-bound CPT were analyzed on a 
HPLC system (Agilent) equipped with a fluorescence detector (excitation 370 nm, 
emission 440 nm) and a reverse phase column (Synergi 4 µm Hydro-RP 80 Å, 
Phenomenex) complete with guard column. 50% acetonitrile, 50% potassium phosphate 
buffer (10 mM, pH 4) was used as the eluent at a flow rate of 0.5 ml/min.  
Absorbance and other fluorescence measurements were taken on a microplate 
reader (Infinite 200, Tecan). 
 
3.3.2 Cellular Uptake Studies 
24 well plates were seeded with either BT-474 (in RPMI-1640 medium 
supplemented with 10% fetal calf serum) or MCF-7 (in Dulbecco’s Modified Eagle 
medium supplemented with 10% fetal calf serum) (Cellgro, Manassas, VA) at 20,000 
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cells per well and kept at 37 oC in a humidified oven with 5% CO2. After 40 h, media 
were replaced with 0.3 ml of fresh media containing either medium MAP-CPT 
nanoparticles (40 µg CPT/ml), medium MAP-CPT nanoparticles with free Herceptin at 
10 mg/ml, targeted MAP-CPT nanoparticles (40 µg CPT/ml) at varying targeting 
densities or targeted MAP-CPT nanoparticles with free Herceptin at 10 mg/ml. 
Transfection was conducted for 30 min at 37 oC. Formulations were then removed and 
cells washed twice with cold PBS. 200 µl of RIPA buffer was added per well for cell 
detachment and lysis. Lysed cells were incubated at 4 oC for 15 min and centrifuged at 
14,000 g for 10 min at 4 oC. A portion of the supernatant was used for protein 
quantification via BCA assay. To another portion was added an equal amount of 0.1 N 
NaOH, this was incubated at room temperature overnight and fluorescence was measured 
at 370/440 nm using known concentrations of medium MAP-CPT nanoparticles as 
standard.  
 
3.3.3 In Vitro Release Studies  
Release of CPT from short, medium, long MAP-CPT nanoparticles and targeted 
MAP-CPT nanoparticles were conducted at 0.32 mg CPT/ml in 1x PBS at pH 6.5, 7 or 
7.4; BALB/c mice plasma, human plasma, and 1x PBS at pH 7.4 containing 3 mg/ml of 
low density lipoprotein (LDL), or 100 units/ml of Butyrylcholinesterase (BCHE) or a 
combination of LDL and BCHE. 
Media pipetted into 96 well plates were incubated at 37 oC in a humidified oven 
for 2 h for equilibration. Formulations were mixed into the relevant media and placed 
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back into the oven. Samples were taken at predetermined time points and immediately 
frozen at -80 oC until time for analysis. For release in BALB/c mice plasma and in human 
plasma, incubation was carried out in a humidified oven at 37 oC with 5% CO2 to 
maintain the carbonic acid/bicarbonate buffer system, the major pH buffer system in 
plasma at physiological pH levels.  
The amount of unconjugated CPT was determined by first mixing 10 µl of sample 
with 10 µl of 0.1 N HCl and incubating at room temperature for 30 min. 80 µl of 
methanol was then added and the mixture incubated at room temperature for 3 h for 
protein precipitation. This mixture was centrifuged at 14,000 g for 10 min at 4 oC, 
supernatant was filtered with a 0.45 µm filter (Millex-LH), diluted 20 fold with methanol 
and 10 µl of the resulting solution injected into HPLC. The peak area of the eluted CPT 
(at 7.8 min) was compared to that of control. To measure the total amount of CPT, 10 µl 
of sample was mixed with 6.5 µl of 0.1 N NaOH. This solution was incubated at room 
temperature for 1 h for CPT to be released from parent polymer. 10 µl of 0.1 N HCl was 
then added to convert the carboxylate CPT form to the lactone form. 73.5 µl of methanol 
was subsequently added and mixture incubated for 3 h at room temperature. The sample 
was then centrifuged and processed as above. Polymer-bound CPT concentration was 
determined from the difference between total CPT and unconjugated CPT concentrations. 
 
3.3.4 Cytotoxicity Assays 
Cells were kept at 37 oC in a humidified oven with 5% CO2. BT-474, MCF-7, 
SKBR-3 and MDA-MB-231 cell lines were incubated in RPMI-1640 medium, 
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Dulbecco’s Modified Eagle medium, McCoy’s 5A Modified medium and Dulbecco’s 
Modified Eagle medium respectively (all supplemented with 10% fetal calf serum). 3,000 
cells per well were plated into 96 well plates. After 24 h, media was removed and 
replaced with fresh media containing different concentrations of either medium MAP, 
nitroPBA-PEG, CPT, medium MAP-CPT nanoparticles, targeted MAP-CPT 
nanoparticles or Herceptin. After 72 h of incubation, formulations were replaced with 
fresh media, and 20 µl of CellTiter 96® AQueous One Solution cell proliferation assay 
(Promega) was added per well. This was incubated for 2 h in a humidified oven at 37 oC 
with 5% CO2 before absorbance measurements at 490 nm. Wells containing untreated 
cells were used as controls.  
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3.4 Results and Discussion 
3.4.1 Cellular Uptake Studies 
BT-474, a HER2 overexpressing human breast cancer cell line, was used to 
examine the cellular uptake of the Herceptin targeted MAP-CPT nanoparticles versus the 
non-targeted nanoparticles. MCF-7, a HER2 negative breast cancer cell line, was used as 
a negative control. It was observed that one Herceptin-PEG-nitroPBA per nanoparticle 
was sufficient to achieve ca. 70% greater uptake in BT-474 cell line compared to the non-
targeted nanoparticle (Figure 3.1A).  
Uptake of the targeted MAP-CPT nanoparticles in BT-474 cells showed inhibition 
in the presence of free Herceptin (Figure 3.1B). In contrast, uptake of the non-targeted 
MAP-CPT nanoparticles in MCF-7 exhibited no dependence on targeting or on presence 
of free Herceptin (Figure 3.1B). These data indicate that there is receptor mediated 
uptake in the BT-474 cells by the targeted MAP-CPT nanoparticles via engagement of 
the HER2 receptor. Cellular uptake of both the targeted and non-targeted MAP-CPT 
nanoparticles also occurred via nonspecific fluid phase endocytosis. 
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Figure 3.1 Cellular uptake studies. (A) Targeted MAP-CPT nanoparticles at increasing 
ratio of Herceptin-PEG-nitroPBA to nanoparticle in BT-474. (B) Medium MAP-CPT 
nanoparticles or targeted MAP-CPT nanoparticles with or without free Herceptin (10 
mg/ml) in BT-474 and MCF-7 cell lines.  
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3.4.3 In Vitro Release Studies 
Release of CPT from the short, medium, long MAP-CPT nanoparticles and from 
the targeted MAP-CPT nanoparticles all exhibited first-order kinetics. Release half-lives 
of CPT from the short, medium and long MAP-CPT nanoparticles were very similar in 
all conditions tested, while longer half-lives for the targeted MAP-CPT nanoparticles 
were observed (Table 3.1).  
A strong dependence of release rate with pH was observed (Table 3.1). As the pH 
increased from 6.5 to 7.4, the release half-lives reduced from 338 h to 58 h for the short, 
medium and long MAP-CPT nanoparticles. These data indicate that hydrolysis plays an 
important role in the release of CPT.  
 
 
Table 3.1 In vitro release half-lives (t1/2) of CPT from short, medium and long MAP-CPT 
nanoparticles, and from targeted MAP-CPT nanoparticles in various media. 
Abbreviations: PBS, phosphate buffered saline; LDL, low density lipoprotein; BCHE, 
PBS t1/2 (h) pH 6.5 pH 7 pH 7.4 
Short, medium, long 
MAP-CPT 
338 178 58 
Targeted MAP-CPT 396 204 78 
Plasma t1/2 (h) Mice  Human  
Short, medium, long 
MAP-CPT 
59 38 
Targeted MAP-CPT  63 46 
PBS pH 7.4  t1/2 (h) LDLa BCHEb LDL + BCHEc 
Short, medium, long 
MAP-CPT 
45 61 44 
Targeted MAP-CPT 62 76 62 
! 55!
Butyrylcholinesterase. aPBS, pH 7.4, containing 3 mg/ml LDL. bPBS, pH 7.4, containing 
100 units/ml BCHE. cPBS, pH 7.4, containing 3 mg/ml LDL and 100 units/ml BCHE. 
 
A release half-life of 59 h was observed in BALB/c mice plasma, while a 
significantly lower half-life of 38 h was obtained in human plasma for the short, medium 
and long MAP-CPT nanoparticles (Table 3.1). It is known that mice plasma contains 
more esterase activity than human plasma, while human plasma contains more fat than 
mice plasma. Therefore, to understand the differences in release rates between human and 
mice plasma, the contributions of esterase and fat to CPT release rates were individually 
tested. Butyrylcholinesterase (BCHE) is present in both mice and human plasma and was 
used to test esterase contribution to the release rate. Low density lipoprotein (LDL) was 
chosen to test the contribution of fat to the release rate. These components were 
constituted in PBS (pH 7.4). It was found that the presence of BCHE did not affect 
release rate (half-life of 61 h compared to 58 h in PBS, pH 7.4, for the short, medium and 
long MAP-CPT nanoparticles). However, the addition of LDL dramatically increased the 
release rates (Table 3.1). This effect is likely due to nanoparticle disruption by competing 
hydrophobic interactions. Therefore, nanoparticle disruption by the presence of fat, and 
the subsequent CPT cleavage by hydrolysis appears to be another main mechanism of 
CPT release from MAP-CPT nanoparticles.  
In vitro release from the Herceptin targeted MAP-CPT nanoparticles shows 
longer half-lives than the non-targeted versions (Table 3.1). It is possible that the 
presence of Herceptin with a pI of 9.2 [17] increased the stability of the negatively 
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charged nanoparticles by electrostatic interactions, and thus shielded the nanoparticles 
from some of the hydrolysis and/or competing hydrophobic interactions. 
 
3.4.3 Cytotoxicity Assays 
In vitro cytotoxicities of medium MAP, nitroPBA-PEG, CPT, medium MAP-CPT 
nanoparticles, targeted MAP-CPT nanoparticles and Herceptin were evaluated in two 
HER2+ breast cancer cell lines (BT-474, SKBR-3) and two HER2- breast cancer cell 
lines (MCF-7, MDA-MB-231) (Table 3.2).  
 
 
Table 3.2 IC50 values of medium MAP, nitroPBA-PEG, CPT, medium MAP-CPT 
nanoparticles, targeted MAP-CPT nanoparticles and Herceptin in a range of breast cancer 
cell lines.  
 
Medium MAP and nitroPBA-PEG gave IC50 values of above 500 µM and 1000 
µM (highest concentrations tested), respectively (Table 3.2), indicating minimal toxicity. 
IC50 concentrations of CPT, medium MAP-CPT nanoparticles and targeted MAP-CPT 
MCF-7 MDA-MB-231 SKBR-3 BT-474 
HER2 expression - - + + 
IC50 
(µM) 
Medium MAP >500 >500 >500 >500 
nitroPBA-PEG >1000 >1000 >1000 >1000 
CPT 0.3 0.1 0.03 4 
Medium MAP-CPT 0.5 0.6 0.2 40 
Targeted MAP-CPT 0.5 0.6 0.1 6 
Herceptin no effect no effect cytostatic cytostatic 
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nanoparticles were based on the content of the CPT. It is noted that CPT was released 
gradually from medium MAP-CPT nanoparticles and targeted MAP-CPT nanoparticles 
(see In Vitro Release Studies). Additionally, nanoparticle uptake by cells results in long 
release times due to the acidic nature of the endosomes. These factors contribute to the 
observed higher IC50 values for the medium MAP-CPT nanoparticles and targeted MAP-
CPT nanoparticles compared to CPT (Table 3.2). In HER2+ cell lines, the targeted MAP-
CPT nanoparticles gave lower IC50 values compared to MAP-CPT alone, while in HER2- 
cell lines, targeting did not affect the IC50. BT-474 was the most resistant cell line to CPT, 
and consequently to medium MAP-CPT nanoparticles. The cytostatic nature of Herceptin 
was observed at the lowest Herceptin concentration tested at 0.001 µM in HER2+ cell 
lines, while no effect was observed in HER2- cell lines at Herceptin concentrations of up 
to 0.5 µM. 
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3.5 Conclusions 
Targeted MAP-CPT delivery system was characterized by in vitro studies. It was 
found that a single Herceptin targeting agent is sufficient to achieve greater than 70% 
cellular uptake of nanoparticles compared to control in BT-474, a HER2 overexpressing 
cell line, by cellular uptake studies. The main mechanisms of CPT release from MAP-
CPT nanoparticles were found to be hydrolysis and particle disruption by the presence of 
fat by in vitro release studies. Cytotoxicity studies conducted in HER2 overexpressing 
breast cancer cells lines indicate lower IC50 values when treated with Herceptin targeted 
nanoparticles compared to that treated with the non-targeted version; while the IC50 
values for HER2 negative cells lines are unaffected by the addition of the Herceptin 
targeting agent. 
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4.1 Abstract  
We have developed a new method for assembling targeted nanoparticles that 
utilizes the complexation between targeting agents that contain boronic acids and 
polymer-drug conjugates that possess diols. In this chapter, we report the first in vivo, 
antitumor results of a targeted nanoparticle formed via this new assembly methodology. 
An antibody targeted nanoparticle consisting of a single Herceptin antibody targeting 
agent and a mucic acid containing polymer-conjugate of camptothecin (MAP-CPT) is 
evaluated in nude mice bearing HER2 overexpressing BT-474 human breast cancer 
tumors. Single antibody targeted and non-targeted MAP-CPT nanoparticles show similar 
biodistributions at 4 and 24 h after intravenous tail vein injection. However, confocal 
imaging of tumor sections shows faster cancer cellular accumulation of CPT when the 
targeting agent is present on the nanoparticle. This single Herceptin antibody targeted 
MAP-CPT nanoparticle system carries ca. 60 CPT molecules per nanoparticle and shows 
prolonged in vivo pharmacokinetics with an elimination half-life of 21.2 h and AUC 
value of 2766 µg*h/ml at a 10 mg CPT/kg tail vein injection in mice. The maximum 
tolerated dose (MTD) of the targeted MAP-CPT nanoparticle is found to be 8 mg CPT/kg. 
Animals treated with non-targeted MAP-CPT nanoparticles at 8 mg CPT/kg show tumor 
growth inhibition (mean tumor volume of 63 mm3) when compared to Irinotecan at 80 
mg/kg (mean tumor volume of 575 mm3) and CPT at 8 mg/kg (mean tumor volume of 
808 mm3). Herceptin antibody treatment at 5.9 mg/kg results in 5 out of 8 mice having 
tumors being completely regressed, and a mean tumor volume of 60 mm3 at the end of 
study. Non-targeted MAP-CPT nanoparticles at 1 mg CPT/kg did not show tumor 
inhibition. However, the single antibody Herceptin-MAP-CPT nanoparticles (5.9 mg 
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Herceptin/kg and 1 mg CPT/kg) resulted in all treated mice revealing complete tumor 
regression at the end of study. These results demonstrate that single antibody containing 
nanoparticles can be formulated, and that these targeted nanoparticles can show 
significant antitumor efficacy.  
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4.2 Introduction 
Camptothecin is a highly potent, naturally occurring anticancer alkaloid that acts 
by inhibiting both DNA enzyme topoisomerase I and HIF-1α activities (1, 2). However, 
its systemic delivery is problematic due to its low aqueous solubility and nonspecific 
toxicity. In addition, its anticancer activity of CPT is derived only from its lactone form. 
The inactive ring-opened carboxylate form is favored at physiological pH. Furthermore, 
the carboxylate form binds to human serum albumin (HSA) leading to further CPT ring 
opening and deactivation (3). The FDA approved CPT derivatives Irinotecan and 
Topotecan are used to treat solid tumors in a variety of cancers, but numerous toxicities 
remain problematic and play a significant role in their clinical efficacy and safety (4, 5).  
CPT conjugates to various polymers have been and are currently being evaluated 
in clinical trials for the treatment of solid tumors (6-9). All of these molecular conjugates 
and nanoparticles seek to exploit the enhanced permeability and retention (EPR) effect 
that causes the preferential accumulation of macromolecules/nanoparticles in solid 
tumors (10). Active targeting can be gained by functionalizing the surface of 
nanoparticles with ligands against over-expressed or specific receptors on tumor cell 
surfaces. Studies show that active targeting improves the efficacy of nanoparticle 
therapeutics by increasing the cellular uptake of the targeted nanoparticles compared with 
non-targeted nanoparticles with similar size and surface charge (11-13).  
In the past years, antibody targeted therapy has received wide attention due to its 
improved clinical results. One example is the use Herceptin® (Trastuzumab) in 
combination with chemotherapy or as a single agent after adjuvant chemotherapy to treat 
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HER2  (human epidermal growth hormone receptor 2) overexpressing metastatic breast 
cancers (14, 15). Herceptin is an antibody against HER2 tyrosine kinase that is 
overexpressed in 20% to 30% of breast cancers and is associated with resistance to 
therapy and poor prognosis (16, 17). Herceptin containing treatments show better 
response compared to chemotherapy treatments alone, however a significant proportion 
of patients treated either do not respond initially or relapse after a period of clinical 
response (14, 18, 19). This resistance to HER2-based therapy has been attributed to 
signaling through alternate receptor pathways such as insulin-like growth factor-I 
receptor, or aberrant activation of downstream signaling pathways including 
phosphatidylinositol 3-kinase pathway, or expression of truncated form of HER2 receptor, 
p95HER2, or steric hindrance of Herceptin-HER2 receptor interaction (20, 21). 
Recently, there is great interest in antibody-drug conjugates (22, 23) due to the 
combination of the therapeutic effects from an antibody and an anticancer drug. For 
instance, Trastuzumab (Herceptin®) Emtansine, composed of a Herceptin antibody 
conjugated to ca. 3 anticancer drug molecules, DM1 (derivative of maytanosoid), shows 
better clinical response compared to lapatinib and capecitabine in patients with HER2 
overexpressing metastatic breast cancers (24, 25). Antibody targeted nanoparticles can be 
used to increase and protect the payload of anticancer drugs (26-28).  
We have created a targeted nanoparticle delivery system for CPT through the use 
of boronic acid-diol complexation. Hydrophobic CPT conjugated onto a biocompatible 
hydrophilic copolymer of mucic acid and polyethylene glycol (MAP) self-assembled into 
MAP-CPT nanoparticles. The antibody Herceptin is attached to a boronic acid via a 
polyethylene glycol (PEG) spacer, and this boronic acid-containing targeting moiety is 
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complexed with the diol-containing MAP to form a targeted MAP-CPT nanoparticle 
(Scheme 4.1).  
In chapter III, we found that targeting of MAP-CPT nanoparticles via a single 
Herceptin antibody is capable of achieving receptor mediated uptake in BT-474, a HER2 
overexpressing human breast cancer cell line in vitro. To date, no single antibody 
targeted nanoparticle carrying anticancer drugs has been investigated. We therefore 
examine the biodistribution, pharmacokinetics and antitumor efficacy of targeted versus 
non-targeted MAP-CPT nanoparticles in a mouse xenograft model using BT-474, to 
determine whether a single antibody on a nanoparticle can provide targeting in vivo. 
 
 
  
 Scheme 4.1 Schematic of targeted MAP-CPT nanoparticle delivery system. MAP = 
mucic acid and polyethylene glycol copolymer, CPT = camptothecin, BA = boronic acid. 
Representative cryo-EM images are shown. 
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4.3 Experimental  
4.3.1 General 
Breast carcinoma cell line BT-474 was purchased from American Type Culture 
Collection (Manassas, VA). Cells were maintained in RPMI-1640 medium supplemented 
with 10% fetal calf serum (Cellgro, Manassas, VA). Female NCr nude mice were 
purchased from Taconic (Oxnard, CA). 17β-estradiol pellets (0.72 mg, 90 day release) 
were purchased from Innovative Research of America (Sarasota, FL). Herceptin® 
(Trastuzumab) was obtained from Dr. Y. Yen at the City of Hope (Duarte, CA). 
Camptothecin (CPT) was obtained from Boehringer Ingelheim (Ingelheim, Germany). 
Irinotecan hydrochloride was purchased from Sigma (St Louis, MO). Goat serum was 
obtained from Vector Laboratories (Burlingame, CA). Rat anti-PEG primary antibody 
was purchased from AbCam (Cambridge, MA). Alexa Fluor 488 goat anti-rat IgM 
secondary antibody, Alexa Fluor 633 goat anti-human IgG secondary antibody and 
Prolong Gold Antifade reagent were obtained from Invitrogen (Grand Island, NY). All 
other reagents were obtained from Sigma (St Louise, MO) unless otherwise stated. 
Medium MAP and nitroPBA-PEG (3-amide-PEG5kDa, 5-nitrophenylboronic 
acid); short, medium and long MAP-CPT nanoparticles; and targeted MAP-CPT 
nanoparticles were synthesized as before (Chapter II).  
Concentrations of unconjugated CPT and polymer-bound CPT were analyzed on a 
HPLC system (Agilent) equipped with a fluorescence detector (excitation 370 nm, 
emission 440 nm) and a reverse phase column (Synergi 4 µm Hydro-RP 80 Å, 
! 68!
Phenomenex) complete with guard column. 50% acetonitrile, 50% potassium phosphate 
buffer (10 mM, pH 4) was used as the eluent at a flow rate of 0.5 ml/min.  
All animals were treated as per National Institute of Health Guidelines for Animal 
Care and approved by the California Institute of Technology Institutional Animal Care 
and Use Committee. 
 
4.3.2 Pharmacokinetics in BALB/c Mice 
The nanoparticles formulated in 0.9 wt% NaCl (non-targeted nanoparticles) or 
PBS (targeted MAP-CPT nanoparticles) were administered via bolus, tail vein injection 
into 12-16 weeks old female BALB/c mice. At predetermined time points, blood was 
collected via saphenous vein bleed with blood collection tubes (Microvette CB 300 
EDTA, Sarstedt). Samples were immediately centrifuged at 10,000 g, 4 oC for 15 min and 
supernatant removed and stored at -80 oC until time for analysis.  
The amount of unconjugated CPT was determined by first mixing 10 µl of sample 
with 10 µl of 0.1 N HCl and incubating at room temperature for 30 min. 80 µl of 
methanol was then added and the mixture incubated at room temperature for 3 h for 
protein precipitation. This mixture was centrifuged at 14,000 g for 10 min at 4 oC, 
supernatant was filtered with a 0.45 µm filter (Millex-LH), diluted 20 fold with methanol 
and 10 µl of the resulting solution injected into HPLC. The peak area of the eluted CPT 
(at 7.8 min) was compared to that of control. To measure the total amount of CPT, 10 µl 
of sample was mixed with 6.5 µl of 0.1 N NaOH. This solution was incubated at room 
temperature for 1 h for CPT to be released from parent polymer. 10 µl of 0.1 N HCl was 
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then added to convert the carboxylate CPT form to the lactone form. 73.5 µl of methanol 
was subsequently added and mixture incubated for 3 h at room temperature. The sample 
was then centrifuged and processed as above. Polymer-bound CPT concentration was 
determined from the difference between total CPT and unconjugated CPT concentrations. 
Non-compartmental modeling software PK Solutions 2.0 by Summit Research 
Services (Montrose, CO) was used for pharmacokinetic data analysis.  
 
4.3.3 Determination of Maximum Tolerable Dose (MTD) in Nude Mice 
12 weeks old female NCr nude mice were randomly divided into thirteen groups 
containing five mice each. Formulations medium MAP or nitroPBA-PEG at 200 mg/kg, 
short MAP-CPT nanoparticles at 10, 15 or 20 mg/kg (CPT basis), medium MAP-CPT 
nanoparticles at 8, 10 or 15 mg/kg (CPT basis), long MAP-CPT nanoparticles at 5, 8 or 
10 mg/kg (CPT basis) and targeted MAP-CPT nanoparticles at 8 or 10 mg/kg (CPT basis) 
were administered on day 0 and day 7 via intravenous tail vein injection. All injections 
were formulated in 0.9 w/v% saline except for targeted MAP-CPT which was formulated 
in PBS, pH 7.4. Weight and health of the mice were recorded and monitored daily for 2 
weeks after the start of the treatment. MTD was defined as the highest dose resulting in 
less than 15% body weight loss and with no treatment related deaths. Animals were 
euthanized when criteria for MTD was exceeded or at the end of the study by CO2 
asphyxiation. 
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4.3.4 Biodistribution in Nude Mice 
7 weeks old NCr nude mice were transplanted subcutaneously with 17β-estradiol 
pellets. After 2 days, BT-474 carcinoma cells suspended in RPMI-1640 medium were 
injected subcutaneously into the right front flank at 10 million cells/animal. Treatment 
began a day after the tumors reached an average size of 260 mm3. Animals were 
randomized into two groups of six mice per group and treated via intravenous tail vein 
injections with either medium MAP-CPT nanoparticles at 5 mg CPT/kg (in PBS, pH 7.4) 
or targeted MAP-CPT nanoparticles at 5 mg CPT/kg and 29 mg Herceptin/kg (in PBS, 
pH 7.4). After 4 h and 24 h, blood was collected from three animals from each group via 
saphenous vein bleed. Animals were then euthanized by CO2 asphyxiation and perfused 
with PBS. Tumor, lung, heart, spleen, kidney and liver were harvested and sectioned into 
two equal sized pieces. One piece was embedded in Tissue-Tek® OCT (Sakura) and the 
other collected in Eppendorf tubes, both were frozen immediately at -80 oC until time for 
processing. 
Organs were weighed and 100 mg of each were placed in Lysing Matrix A 
homogenizer tubes containing an added ¼ inch ceramic sphere (MP Biomedicals, Solon, 
Ohio). 1 ml of RIPA lysis buffer (Thermo Scientific) was added and tissues were 
homogenized using a FastPrep®-24 homogenizer (MP Biomedicals, Solon, Ohio) at 6 
m/s for 30 s. This was repeated for 3 times with 1 min of cooling on ice in between each 
round. Samples were then centrifuged at 14,000 g for 15 min at 4 oC. The amount of 
unconjugated CPT was determined by first mixing 10 µl of the supernatant with 10 µl of 
0.1 N HCl and incubating at room temperature for 30 min. 80 µl of methanol was then 
added and the mixture incubated at room temperature for 3 h for protein precipitation. 
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This mixture was centrifuged at 14,000 g for 10 min at 4 oC, supernatant was filtered with 
a 0.45 µm filter (Millex-LH) and 10 µl of the resulting mixture injected into HPLC. The 
peak area of the eluted CPT (at 7.8 min) was compared to that of control. To measure the 
total amount of CPT, 10 µl of sample was mixed with 6.5 µl of 0.1 N NaOH. This 
solution was incubated at room temperature for 1 h for CPT to be released from parent 
polymer. 10 µl of 0.1 N HCl was then added to convert carboxylate CPT form to lactone 
form. 73.5 µl of methanol was subsequently added and mixture incubated for 3 h at room 
temperature. The sample was then centrifuged and processed as above.  
 
4.3.5 Tumor Processing and Confocal Imaging 
Tumors were sectioned using a cryostat to a thickness of 20-30 µm. The tumor 
sections were placed on Superfrost Plus slides (Fisher Scientific, Hampton, NH) and 
stored at -80 oC until time for processing.  Slides were defrosted and tissue sections were 
fixed directly onto the slide for 15 min with a 10% formalin solution. The slides were 
then washed three times with PBS for 5 min each, and blocked for 1 h in a 5% goat serum 
blocking buffer. A rat anti-PEG primary antibody that recognizes internal PEG units at 14 
µg/ml was placed on the section and incubated at 4 oC overnight. This was followed by 
three PBS washes and 1 h incubation with 2 µg/ml of Alexa Fluor 488 goat anti-rat IgM 
secondary antibody. The slides were then washed three times with PBS, and incubated 
for 1 h with 2 µg/ml of Alexa Fluor 633 goat anti-human IgG secondary antibody to 
visualize Herceptin. The slides were washed three more times with PBS, mounted with a 
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Prolong Gold Antifade reagent and stored at 4 oC until time for imaging. (This was 
performed by Aaron Gale from the Davis lab). 
Images were acquired with a Zeiss LSM 510 Meta Confocal Microscope (Carl 
Zeiss, Germany) using a 63x Plan-Neofluor oil objective.  2-Photon excitation at 720 nm 
(emission filter BP 390-465 nm) was used to detect CPT. Excitation at 488 nm (emission 
filter LP 530) and at 633 nm (emission filter BP 645-700 nm) were used to detect PEG 
and Herceptin respectively. All laser and gain settings were set at the beginning of 
imaging and were unchanged.  Image analysis was performed on Zeiss lsm image 
browser. (This was performed by Devin Wiley from the Davis lab). 
 
4.3.6 Antitumor Efficacy Study in Nude Mice 
17β-estradiol pellets were transplanted subcutaneously into 7 weeks old NCr nude 
mice. After 2 days, BT-474 human breast cancer cells suspended in RPMI-1640 medium 
were injected subcutaneously into the right front flank at 10 million cells/animal. 
Treatment began a day after tumors reached an average size of 250 mm3. Animals were 
randomly divided into nine groups with six to eight mice per group and treated with 
either, MAP-CPT nanoparticles at 1 mg or 8 mg/kg (CPT basis, in PBS, pH 7.4), CPT at 
8 mg/kg (dissolved in 20% DMSO, 20% PEG 400, 30% ethanol and 30% 10 mM pH 3.5 
phosphoric acid), Irinotecan at 80 mg/kg (in 5 w/v% dextrose solution, D5W), Herceptin 
at 2.9 or 5.9 mg/kg (in PBS, pH 7.4), targeted MAP-CPT nanoparticles at 0.5 mg CPT/kg 
and 2.9 mg Herceptin/kg or 1 mg CPT/kg and 5.9 mg Herceptin/kg (in PBS, pH 7.4), or 
saline. All treatments were freshly prepared and given via intravenous tail vein injection. 
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Injections were standardized at 150 µl per 20 g body weight of mice. Treatments 
containing Herceptin were given once per week for 2 weeks, all other groups were given 
once per week for 3 weeks. Tumor sizes were recorded thrice a week using caliper 
measurements (length x width2/2) and health of the animals was continuously monitored. 
Animals were euthanized when tumor volumes exceeded 1000 mm3. 6 weeks after 
beginning of the treatment, animals were euthanized by CO2 asphyxiation.  
When animals exited the study due to tumor size exceeding limit, treatment 
related or non-treatment related deaths, the last tumor volume value recorded was 
included in the subsequent time points. Two-tailed statistical analyses were conducted at 
P = 0.05. Results were considered significant at 0.01 ≤ P ≤ 0.05 and highly significant at 
P < 0.01.  
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4.4 Results and Discussion 
4.4.1 Pharmacokinetics in BALB/c Mice 
Plasma pharmacokinetic studies of short, medium, long MAP-CPT nanoparticles 
and targeted MAP-CPT nanoparticles at 10 mg/kg (CPT basis) injections were conducted 
in female BALB/c mice (Figure 4.1). Non-compartmental modeling was used for data 
analysis (Table 4.1). 
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Figure 4.1 Plasma pharmacokinetics of short, medium and long MAP-CPT nanoparticles 
and targeted MAP-CPT nanoparticles in BALB/c mice at 10 mg CPT/kg injections. Free 
CPT injected at 10 mg/kg into CD2F1 mice is shown as comparison (30). (A) Plasma 
concentration of polymer-bound CPT as a function of time. (B) Plasma concentration of 
unconjugated CPT as a function of time.  
 
Polymer-bound CPT for all nanoparticles displayed a biphasic profile with a fast 
redistribution phase (α) and a long elimination phase (β) (Figure 4.1A). The elimination 
phase for medium and long MAP-CPT nanoparticles were particularly prolonged with 
half-lives of 16.6 and 17.6 h respectively and high AUC values of 2298 and 3636 
µg*h/ml, respectively. Additionally, they show low volume of distributions and clearance 
rates. 24 h after injection, 11.3% of injected dose of medium MAP-CPT nanoparticles 
and 20.5% of injected dose of long MAP-CPT nanoparticles were still circulating in 
plasma as polymer-bound CPT. In contrast, mice injected with CPT alone at 10 mg/kg 
showed fast clearance, with an AUC of only 1.6 µg*h/ml and 0.01% of injected dose 
remaining in circulation after 8 h (modified from reference 30). Targeting of medium 
MAP-CPT nanoparticles affected the pharmacokinetic profile by increasing the 
redistribution phase and prolonging the elimination phase to 21.2 h with a high AUC 
value of 2766 µg*h/ml. The amounts of unbound CPT in plasma for all nanoparticles 
were low at all time points (Figure 4.1B). 
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Table 4.1 Plasma pharmacokinetic parameters of polymer-bound CPT for short, medium 
and long MAP-CPT nanoparticles, and targeted MAP-CPT nanoparticles compared to 
CPT alone.!Abbreviations: t1/2 α, redistribution half-life; t1/2 β, elimination half-life; AUC, 
area under curve; Vd, volume of distribution and Cl, systemic clearance. 
 
4.4.2 Determination of Maximum Tolerable Dose (MTD) in Nude Mice 
MTD values were determined in female NCr nude mice and defined as the highest 
dose resulting in less than 15% body weight loss and with no treatment related deaths. 
Mice treated with medium MAP, nitroPBA-PEG, short, medium and long MAP-CPT and 
targeted MAP-CPT were tracked for weight and monitored for health after two weekly 
doses on day 0 and day 7 (Figure 4.2).  
The weight and health of the mice were unaffected by treatment at high doses of 
medium MAP or nitroPBA-PEG indicating minimal toxicity of these polymeric 
components. For groups containing CPT, maximum weight loss appeared 3 to 5 days 
after each treatment. Most of the groups gained back the lost weight. If body weight loss 
continued and exceeded an average of 15%, then the study was concluded. Some mice in 
groups treated with medium MAP-CPT at 15 mg/kg and long MAP-CPT at 10 mg/kg 
showed diarrhea and appeared weak. All other mice appeared healthy. MTD values were 
t1/2 α (h) t1/2 β (h) AUC (µg h/ml) Vd (ml) Cl (ml/h) 
Short MAP-CPT 0.6 13.2 728 6.5 0.34 
Medium MAP-CPT 1.0 16.6 2298 2.6 0.11 
Long MAP-CPT 0.4 17.6 3636 1.7 0.07 
Targeted MAP-CPT 0.2 21.2 2766  2.8 0.09 
CPT - - 1.6 5538 156 
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found to be 20, 10, 8 and 8 mg/kg (on CPT basis) for short, medium, long MAP-CPT and 
targeted MAP-CPT respectively (Table 4.2).  
 
 
Figure 4.2 Determination of maximum tolerable dose (MTD) in female NCr nude mice. 
Arrows indicate treatments; all groups containing CPT are based on mg CPT/kg. 
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medium MAP-CPT 10mg/kg 
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Table 4.2 Treatment response for maximum tolerable dose (MTD) study. aAll groups 
containing MAP-CPT are based on mg CPT/kg. bMaximum percent body weight loss. 
cAnimals culled due to exceeding 15% body weight loss. 
 
4.4.3 Biodistribution in Nude Mice 
The average percentage injected dose (ID) of total CPT per gram of tumor, heart, 
liver, spleen, kidney and lung is shown in Figure 4.3. After 4 h, 5.3 and 5.2% ID of total 
CPT were present in tumors for mice treated with MAP-CPT nanoparticles and targeted 
MAP-CPT nanoparticles respectively. 24 h after treatment, 2.6% ID of total CPT 
remained in tumors for MAP-CPT nanoparticles, while 3.2% ID of total CPT were found 
in tumors for targeted MAP-CPT nanoparticles. This indicates that targeting on 
nanoparticles does not increase tumor localization compared with non-targeted version 
and is consistent with literature observations (11-13). Animals treated with MAP-CPT 
nanoparticles and targeted MAP-CPT nanoparticles show similar distribution of CPT in 
Dose (mg/kg)a Max % weight loss (day)b Death 
medium MAP 200 -1.1 (11) 0 
nitroPBA-PEG 200 -0.5 (2) 0 
short MAP-CPT 10 -4.5 (2) 0 
short MAP-CPT 15 -6.1 (10) 0 
short MAP-CPT 20 -10.2 (12) 0 
medium MAP-CPT 8 -6.8 (10) 0 
medium MAP-CPT 10 -14.9 (12) 0 
medium MAP-CPT 15 -18.4 (4) culledc 
long MAP-CPT 5 -4.8 (4) 0 
long MAP-CPT 8 -9.2 (12) 0 
long MAP-CPT 10 -16.5 (10) culledc 
targeted MAP-CPT 8 -5.2 (4) 0 
targeted MAP-CPT 10 -15.2 (9)  culledc 
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heart, liver, kidney and lung. There was, however, a comparatively significant amount of 
total CPT accumulation in the spleen for targeted MAP-CPT versus non-targeted at 24 h. 
This effect has been observed previously for humanized antibodies in mice (29). 
 
Figure 4.3 Biodistribution of MAP-CPT nanoparticles (5 mg CPT/kg) and targeted 
MAP-CPT nanoparticles (5 mg CPT/kg, 29 mg Herceptin/kg) after 4 and 24 h of 
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treatment. (A) Percent injected dose (ID) of total CPT per gram of tumor, heart, liver, 
spleen, kidney or lung. (B) Percentage of total CPT in each organ that is unconjugated in 
tumor, heart, liver, spleen, kidney and lung. (C) Plasma concentration of total CPT. (D) 
Percentage of total CPT that is unconjugated in plasma. 
 
Figure 4.3B shows the average percentage of total CPT that was unconjugated in 
tumor, heart, liver, spleen, kidney and lung. The percentage unconjugated in heart, liver, 
spleen, kidney and lung were low at both 4 h and 24 h indicating fast clearance of free 
CPT from these organs. In tumor at 24 h, there were significantly higher percentages of 
unconjugated CPT for both MAP-CPT and targeted MAP-CPT nanoparticles compared 
to that at 4 h. The retention of free CPT within the tumor suggests cellular accumulation 
of CPT. The targeted nanoparticles show slightly higher percentage of unconjugated CPT 
in tumors for mice compared to the non-targeted nanoparticles at both 4 and 24 h. 
The total plasma CPT concentration and percentage of total plasma CPT that was 
unconjugated were similar for both MAP-CPT and targeted MAP-CPT nanoparticles 
(Figure 4.3C). After 4 h, 17 and 20 µg/ml of total CPT remained in plasma for MAP-CPT 
and targeted MAP-CPT nanoparticles respectively. After 24 h, the amounts of total CPT 
remaining in plasma were the same for both MAP-CPT and targeted MAP-CPT 
nanoparticles at 12 µg/ml. The percentage of total CPT that is unconjugated in plasma 
was below 3% for all conditions indicating small release and fast clearance of 
unconjugated CPT from plasma (Figure 4.3D). 
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4.4.4 Confocal Imaging 
 
Figure 4.4 Confocal immunofluorescence microscopy of BT-474 tumor sections taken 
from NCr nude mice treated with (A) MAP-CPT (5 mg CPT/kg) at 4 h (B) MAP-CPT (5 
mg CPT/kg) at 24 h. (C) Targeted MAP-CPT (5 mg CPT/kg, 29 mg Herceptin/kg) at 4 h. 
(D) Targeted MAP-CPT (5 mg CPT/kg, 29 mg Herceptin/kg) at 24 h. Left panel emission 
440 nm (CPT, pink), center left panel emission 519 nm (MAP, green), center right panel 
emission 647 nm (Herceptin, blue), right panel overlay of images. 
                   CPT                                  MAP                               Herceptin                            Merge!
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BT-474 tumor bearing NCr nude mice were treated with either MAP-CPT (5 mg 
CPT/kg) or targeted MAP-CPT (5 mg CPT/kg, 29 mg Herceptin/kg). After 4 and 24 h, 
mice were euthanized, tumors were removed and processed for confocal 
immunofluorescence imaging. CPT is naturally fluorescent with emission at 440 nm. To 
identify the location of MAP, the PEG within MAP was stained with anti-PEG antibody, 
then stained with secondary antibody containing Alexa Fluor 488 (emission 519 nm). All 
tumor sections were stained for Herceptin with an anti-human IgG labeled with Alexa 
Fluor 633 (emission 647 nm). Tumor section images were all taken at the same laser 
power and gain settings. Representative images are shown for each group in Figure 4.4.  
Figure 4.4A shows tumor section of mice treated with MAP-CPT nanoparticles 
after 4 h. CPT signal was disperse. Signals for CPT and MAP appeared to colocalize in 
the merged image. 24 h after injection, there was accumulation of CPT signal in the form 
of punctate spots (Figure 4.4B). The merged image suggests colocalization of CPT and 
MAP. For mice treated with targeted MAP-CPT nanoparticles, spots indicating CPT 
accumulation were observed after both 4 and 24 h of treatment (Figure 4.4C and 4.4D). 
In the merged images, there was colocalization of CPT and MAP signals. The presence of 
Herceptin in targeted MAP-CPT nanoparticles is indicated by the strong blue signals in 
the Herceptin channel compared with weak background signals in the non-targeted 
version. In addition, the observation of CPT accumulation at both 4 and 24 h time points 
for mice treated with targeted MAP-CPT nanoparticles, while for mice treated with non-
targeted MAP-CPT nanoparticles, accumulation of CPT was only appeared at 24 h 
suggests that the presence of Herceptin targeting may speed up the cellular accumulation 
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of CPT. This is likely through the cellular uptake of nanoparticles via receptor mediated 
endocytosis.  
 
4.4.5 Antitumor Efficacy Study in Nude Mice 
To promote tumor growth in nude mice, 17β-estradiol pellets were implanted two 
days prior to BT-474 tumor cell implantation. Tumors grew rapidly. On day 0 (five days 
after implantation), tumor sizes of each group averaged 250 mm3. Treatments began on 
day 1. Irinotecan was administered at a dose of 80 mg/kg in D5W. CPT is highly 
insoluble in aqueous solutions, therefore it was dissolved in a solution containing 20% 
DMSO, 20% PEG 400, 30% ethanol and 30% 10 mM pH 3.5 phosphoric acid. Irinotecan 
and CPT were both administered via intravenous tail vein injection to be consistent with 
the rest of the treatment groups. A saline treatment group was used as the control. All 
other treatments were administered in PBS, at pH 7.4. Changes in tumor sizes were 
recorded by caliper measurement three times a week and health of the animals were 
continuously monitored (Figure 4.5 and Table 4.3).  
Tumors in control group administered with saline grew rapidly. After 28 days, 
five out of eight mice had tumors exceeding size limit of 1000 mm3. All animals in this 
group were euthanized at this time. 
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Figure 4.5 Antitumor efficacy study in NCr nude mice bearing BT-474 xenograft tumors. 
Mean tumor volume as a function time; groups containing Herceptin received 2 weekly 
doses; all other groups received 3 weekly doses.  
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Group treated with CPT (8 mg/kg) resulted in no tumor inhibition compared to 
that of the control group (P > 0.05). One and three treatment related deaths were recorded 
on day 9 and 16 respectively, as well as four euthanizations due to exceeding tumor size 
limit on day 28. None of the animals survived to the end of the study. 
Irinotecan treated mice at 80 mg/kg showed non-significant tumor inhibition 
compared to control group (P > 0.05). One treatment related death occurred on day 11. 
Tumor sizes reached an average of 575 mm3 by the end of the study. 
Animals receiving MAP-CPT nanoparticles at 8 mg CPT/kg showed highly 
significant tumor inhibition compared to that of control group (P < 0.01). By the end of 
the study the mean tumor size reduced to 63 mm3 and three out of the eight mice treated 
had tumor sizes regressed to zero. Although no death occurred in MTD study using non-
tumor bearing NCr nude mice treated with MAP-CPT nanoparticles at 8 mg CPT/kg, one 
death occurred due to weight loss in this study on day 21.  This maybe because of the 
added tumor burden in this study and/or because mice used in this study were 7 weeks 
old, while in MTD studies, 12 weeks old mice were used. 
 
 
Table 4.3 Antitumor efficacy study in NCr nude mice bearing BT-474 xenograft tumors. 
aNbegin is number of animals at beginning of study, Nend is number of animals surviving to 
Nbegin/Nenda NTRD/NNTRD/Neuthanb  Mean tumor volume
 
(mm3) 
Median tumor volume 
(mm3) 
Nreg to zeroc P vs salined 
MAP-CPT (8 mg/kg) 8/7 1/0/0 63 68 3  0.002 
Irinotecan (80 mg/kg) 8/7 1/0/0 575 479 0  0.242 
CPT (8 mg/kg) 8/0 4/0/4 808 417 0  0.781 
Herceptin (5.9 mg/kg) 8/8 0/0/0 60 0 5  0.003 
Targeted MAP-CPT (1 mg CPT/kg, 5.9 mg Herceptin/kg) 8/7 0/1/0 0 0 7  0.001 
Herceptin (2.9 mg/kg) 6/6 0/0/0 278 245 2  0.026 
Targeted MAP-CPT (0.5 mg CPT/kg, 2.9 mg Herceptin/kg) 6/6 0/0/0 141 187 2  0.005 
Saline  8/0 0/0/8 911 1087 0  - 
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end of study. bNTRD is number of treatment related death, NNTRD is number of non-
treatment related death, Neuthan is number of animals euthanized due to exceeding tumor 
size limit of 1000 mm3. cNreg to zero is number of animals with tumors regressed to zero at 
the end of study. 
 
 
Figure 4.6 Individual tumor volumes for NCr nude mice bearing BT-474 xenograft 
tumors treated with (A) Targeted MAP-CPT nanoparticles (1 mg CPT/kg and 5.9 mg 
Herceptin/kg) and with (B) Herceptin at 5.9 mg/kg. 
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Animals treated with Herceptin at 5.9 mg/kg showed highly significant tumor 
inhibition compared to control group (P < 0.01). On day 11 of treatment, seven out of the 
eight animals treated had tumors regressed to zero. However, by the end of the study, two 
of the regressed tumors relapsed resulting in a total of five animals with tumors at zero 
volume and a group mean tumor volume of 60 mm3 (Figure 4.6). MAP-CPT 
nanoparticles at 1 mg CPT/kg group was terminated early due to no observed antitumor 
effects. Nevertheless, when Herceptin at 5.9 mg/kg was added as a targeting agent via a 
nitroPBA-BA linker onto the MAP-CPT nanoparticles at a low CPT dosage of 1 mg/kg 
(targeted MAP-CPT at 1 mg CPT/kg and 5.9 mg Herceptin/kg group), all tumors 
regressed to zero on day 9 of treatment and remained at zero by the end of the study 
(Figure 4.6). One non-treatment related death occurred on day 37. This result is highly 
significant compared to control group (P < 0.01). The combination of results observed for 
these three groups indicates that there is improved efficacy of the MAP-CPT 
nanoparticles by the addition of the Herceptin targeting agent in addition to the intrinsic 
activity of the Herceptin. 
Animals treated with Herceptin at 2.9 mg/kg resulted in two animals having 
tumors regressed to zero by the end of study. However, the average tumor size increased 
from the beginning of the study to 278 mm3. This result is significant compared to control 
group (0.01 ≤ P ≤ 0.05). When animals were treated with targeted MAP-CPT 
nanoparticles containing 0.5 mg CPT/kg and 2.9 mg Herceptin/kg, two tumors regressed 
to zero. The average tumor size reduced to 141 mm3 by the end of the study. This result is 
highly significant compared to control group (P < 0.01). These results further suggest the 
benefits of targeting in tumor inhibition. 
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5 weeks after 17β-estradiol pellets implantation, several mice irrespective of 
treatment groups were observed to have distended bladder and abdominal bloating. This 
was likely due to the use of 17β-estradiol pellets, which causes hydronephrosis and urine 
retention in athymic nude mice (31). 6 weeks after treatment, conditions became worse 
and more mice were observed to develop distended bladders and abdominal bloating, 
thus animals were euthanized and experiment was terminated. 
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4.5 Conclusions 
Targeted MAP-CPT delivery system was characterized by in vivo studies. Single 
Herceptin antibody targeted and non-targeted MAP-CPT nanoparticles showed similar 
biodistributions at 4 and 24 h after intravenous tail vein injection. However, confocal 
imaging of tumor sections suggested faster tumor cellular accumulation of CPT when the 
targeting agent is present on the nanoparticle. This Herceptin antibody targeted MAP-
CPT nanoparticle system demonstrated prolonged in vivo pharmacokinetics with an 
elimination half-life of 21.2 h and AUC value of 2766 µg*h/ml at a 10 mg CPT/kg tail 
vein injection in mice. Animals treated with non-targeted MAP-CPT nanoparticles at 8 
mg CPT/kg showed significant tumor growth inhibition when compared to Irinotecan at 
80 mg/kg and CPT at 8 mg/kg. Herceptin antibody treatment at 5.9 mg/kg resulted in 5 
out of 8 mice having tumors being completely regressed, and a mean tumor volume of 60 
mm3 at the end of study. Non-targeted MAP-CPT nanoparticles at 1 mg CPT/kg did not 
show tumor inhibition. However, the single antibody Herceptin-MAP-CPT nanoparticles 
(5.9 mg Herceptin/kg and 1 mg CPT/kg) resulted in all treated mice showing complete 
tumor regression at the end of study.  
 
 
 
 
 
! 90!
4.6 References  
(1)! Hsiang,! Y.! H.,! Hertzberg,! R.,! Hecht,! S.,! and! Liu,! L.! F.! (1985)! Camptothecin!Induces!ProteinDLinked!DNA!Breaks!Via!Mammalian!DNA!TopoisomeraseDI.!J#
Biol#Chem!260,!4873D4878.!
(2)! Rapisarda,! A.,! Uranchimeg,! B.,! Scudiero,! D.! A.,! Selby,! M.,! Sausville,! E.! A.,!Shoemaker,! R.! H.,! and! Melillo,! G.! (2002)! Identification! of! small! molecule!inhibitors! of! hypoxiaDinducible! factor! 1! transcriptional! activation! pathway.!
Cancer#Research!62,!4316D4324.!
(3)! Mi,!Z.!H.,!and!Burke,!T.!G.!(1994)!Marked!Interspecies!Variations!Concerning!the! Interactions! of! Camptothecin! with! Serum! Albumins! D! a! FrequencyDDomain!Fluorescence!Spectroscopic!Study.!Biochemistry!33,!12540D12545.!
(4)! Xu,! Y.,! and! VillalonaDCalero,!M.! A.! (2002)! Irinotecan:!mechanisms! of! tumor!resistance!and!novel!strategies!for!modulating!its!activity.!Annals#of#Oncology!
13,!1841D1851.!
(5)! Tian,!Q.,! Zhang,! J.,! Chan,! S.! Y.,! Tan,! T.!M.! C.,!Duan,!W.,!Huang,!M.,! Zhu,! Y.! Z.,!Chan,!E.,!Yu,!Q.,!Nie,!Y.!Q.,!Ho,!P.!C.!L.,!Li,!Q.,!Ng,!K.!Y.,!Yang,!H.!Y.,!Wei,!H.,!Bian,!J.!S.,! and!Zhou,!S.!F.! (2006)!Topotecan! is! a! substrate! for!multidrug! resistance!associated!protein!4.!Curr#Drug#Metab!7,!105D116.!
(6)! Svenson,!S.,!Wolfgang,!M.,!Hwang,!J.,!Ryan,!J.,!and!Eliasof,!S.!(2011)!Preclinical!to! clinical! development! of! the! novel! camptothecin! nanopharmaceutical!CRLX101.!Journal#of#Controlled#Release!153,!49D55.!
! 91!
(7)! Homsi,!J.,!Simon,!G.!R.,!Garrett,!C.!R.,!Springett,!G.,!De!Conti,!R.,!Chiappori,!A.,!Munster,!P.!N.,!Burton,!M.!K.,!Stromatt,!S.,!Allievi,!C.,!Angiulli,!P.,!Eisenfeld,!A.,!Sullivan,! D.! M.,! and! Daud,! A.! I.! (2007)! Phase! I! trial! of! polyDLDglutamate!camptothecin! (CTD2106)! administered! weekly! in! patients! with! advanced!solid!malignancies.!Clinical#Cancer#Research!13,!5855D5861.!
(8)! Yurkovetskiy,! A.! V.,! and! Fram,! R.! J.! (2009)! XMTD1001,! a! novel! polymeric!camptothecin! proDdrug! in! clinical! development! for! patients! with! advanced!cancer.!Advanced#Drug#Delivery#Reviews!61,!1193D1202.!
(9)! Scott,!L.,!Yao,!J.,!Benson,!A.!B.,!Thomas,!A.,!Falk,!S.,!Mena,!R.,!Picus,!J.,!Wright,!J.,!Mulcahy,! M.,! Ajani,! J.,! and! Evans,! T.! (2009)! A! phase! II! study! of! pegylatedDcamptothecin! (pegamotecan)! in! the! treatment! of! locally! advanced! and!metastatic!gastric!and!gastroDoesophageal! junction!adenocarcinoma.!Cancer#
Chemotherapy#and#Pharmacology!63,!363D370.!
(10)! Maeda,!H.,!Wu,!J.,!Sawa,!T.,!Matsumura,!Y.,!and!Hori,!K.!(2000)!Tumor!vascular!permeability! and! the! EPR! effect! in!macromolecular! therapeutics:! a! review.!
Journal#of#Controlled#Release!65,!271D284.!
(11)! Kirpotin,!D.!B.,!Drummond,!D.!C.,!Shao,!Y.,!Shalaby,!M.!R.,!Hong,!K.!L.,!Nielsen,!U.! B.,!Marks,! J.! D.,! Benz,! C.! C.,! and! Park,! J.!W.! (2006)! Antibody! targeting! of!longDcirculating! lipidic! nanoparticles! does! not! increase! tumor! localization!but! does! increase! internalization! in! animal! models.! Cancer# Research! 66,!6732D6740.!
! 92!
(12)! Bartlett,!D.!W.,!Su,!H.,!Hildebrandt,!I.!J.,!Weber,!W.!A.,!and!Davis,!M.!E.!(2007)!Impact! of! tumorDspecific! targeting! on! the! biodistribution! and! efficacy! of!siRNA!nanoparticles!measured!by!multimodality!in!vivo!imaging.!Proceedings#
of# the# National# Academy# of# Sciences# of# the# United# States# of# America! 104,!15549D15554.!
(13)! Choi,!C.!H.! J.,!Alabi,!C.!A.,!Webster,!P.,!and!Davis,!M.!E.! (2010)!Mechanism!of!active! targeting! in! solid! tumors! with! transferrinDcontaining! gold!nanoparticles.!Proceedings#of# the#National#Academy#of#Sciences#of# the#United#
States#of#America!107,!1235D1240.!
(14)! Slamon,!D.! J.,! LeylandDJones,!B.,! Shak,!S.,!Fuchs,!H.,!Paton,!V.,!Bajamonde,!A.,!Fleming,!T.,! Eiermann,!W.,!Wolter,! J.,! Pegram,!M.,! Baselga,! J.,! and!Norton,! L.!(2001)!Use! of! chemotherapy!plus! a!monoclonal! antibody! against!HER2! for!metastatic!breast!cancer!that!overexpresses!HER2.!New#Engl#J#Med!344,!783D792.!
(15)! Smith,!I.,!Procter,!M.,!D!Gelber,!R.,!Guillaume,!S.,!Feyereislova,!A.,!Dowsett,!M.,!Goldhirsch,!A.,!Untch,!M.,!Mariani,!G.,!Baselga,! J.,!Kaufmann,!M.,!Cameron,!D.,!Bell,!R.,!Bergh,!J.,!Coleman,!R.,!Wardley,!A.,!Harbeck,!N.,!Lopez,!R.!I.,!Mallmann,!P.,! Gelmon,! K.,! Wilcken,! N.,! Wist,! E.,! Rovira,! P.! S.,! and! PiccartDGebhart,! M.!(2007)! 2Dyear! followDup! of! trastuzumab! after! adjuvant! chemotherapy! in!HER2Dpositive!breast!cancer:!a! randomised!controlled! trial.!Lancet!369,!29D36.!
! 93!
(16)! Slamon,!D.!J.,!Clark,!G.!M.,!Wong,!S.!G.,!Levin,!W.!J.,!Ullrich,!A.,!and!Mcguire,!W.!L.! (1987)!HumanDBreast! Cancer! D! Correlation! of! Relapse! and! Survival!with!Amplification!of!the!HerD2!Neu!Oncogene.!Science!235,!177D182.!
(17)! Slamon,!D.! J.,!Godolphin,!W.,! Jones,!L.!A.,!Holt,! J.!A.,!Wong,!S.!G.,!Keith,!D.!E.,!Levin,!W.!J.,!Stuart,!S.!G.,!Udove,!J.,!Ullrich,!A.,!and!Press,!M.!F.!(1989)!Studies!of! the! HerD2/Neu! ProtoDOncogene! in! HumanDBreast! and! OvarianDCancer.!
Science!244,!707D712.!
(18)! Cobleigh,!M.!A.,!Vogel,!C.!L.,!Tripathy,!D.,!Robert,!N.!J.,!Scholl,!S.,!Fehrenbacher,!L.,!Wolter,! J.!M.,! Paton,! V.,! Shak,! S.,! Lieberman,! G.,! and! Slamon,!D.! J.! (1999)!Multinational! study! of! the! efficacy! and! safety! of! humanized! antiDHER2!monoclonal! antibody! in!women!who!have!HER2Doverexpressing!metastatic!breast!cancer!that!has!progressed!after!chemotherapy!for!metastatic!disease.!
Journal#of#Clinical#Oncology!17,!2639D2648.!
(19)! Vogel,! C.! L.,! Cobleigh,! M.! A.,! Tripathy,! D.,! Gutheil,! J.! C.,! Harris,! L.! N.,!Fehrenbacher,! L.,! Slamon,!D.! J.,!Murphy,!M.,!Novotny,!W.! F.,! Burchmore,!M.,!Shak,!S.,!Stewart,!S.!J.,!and!Press,!M.!(2002)!Efficacy!and!safety!of!trastuzumab!as! a! single! agent! in! firstDline! treatment! of!HER2Doverexpressing!metastatic!breast!cancer.!Journal#of#Clinical#Oncology!20,!719D726.!
(20)! Nahta,! R.,! Yu,! D.! H.,! Hung,!M.! C.,! Hortobagyi,! G.! N.,! and! Esteva,! F.! J.! (2006)!Mechanisms!of!disease:!understanding!resistance!to!HER2Dtargeted!therapy!in!human!breast!cancer.!Nat#Clin#Pract#Oncol!3,!269D280.!
! 94!
(21)! Pohlmann,! P.! R.,! Mayer,! I.! A.,! and! Mernaugh,! R.! (2009)! Resistance! to!Trastuzumab!in!Breast!Cancer.!Clinical#Cancer#Research!15,!7479D7491.!
(22)! Casi,! G.,! and! Neri,! D.! (2012)! AntibodyDdrug! conjugates:! Basic! concepts,!examples!and!future!perspectives.!Journal#of#Controlled#Release!161,!422D428.!
(23)! Adair,! J.! R.,! Howard,! P.!W.,! Hartley,! J.! A.,!Williams,! D.! G.,! and! Chester,! K.! A.!(2012)!AntibodyDdrug!conjugates!D!a!perfect!synergy.!Expert#Opin#Biol#Th!12,!1191D1206.!
(24)! Phillips,!G.!D.!L.,!Li,!G.!M.,!Dugger,!D.!L.,!Crocker,!L.!M.,!Parsons,!K.!L.,!Mai,!E.,!Blattler,!W.!A.,!Lambert,!J.!M.,!Chari,!R.!V.!J.,!Lutz,!R.!J.,!Wong,!W.!L.!T.,!Jacobson,!F.! S.,! Koeppen,! H.,! Schwall,! R.! H.,! KenkareDMitra,! S.! R.,! Spencer,! S.! D.,! and!Sliwkowski,! M.! X.! (2008)! Targeting! HER2DPositive! Breast! Cancer! with!TrastuzumabDDM1,! an!AntibodyDCytotoxic!Drug! Conjugate.!Cancer#Research!
68,!9280D9290.!
(25)! Verma,!S.,!Miles,!D.,!Gianni,!L.,!Krop,!I.!E.,!Welslau,!M.,!Baselga,!J.,!Pegram,!M.,!Oh,!D.!Y.,!Dieras,!V.,!Guardino,!E.,!Fang,!L.,!Lu,!M.!W.,!Olsen,!S.,!and!Blackwell,!K.!(2012)! Trastuzumab! emtansine! for! HER2Dpositive! advanced! breast! cancer.!
The#New#England#Journal#of#Medicine!367,!1783D1791.!
(26)! Drummond,! D.! C.,! Noble,! C.! O.,! Guo,! Z.,! Hayes,! M.! E.,! ConnollyDIngram,! C.,!Gabriel,!B.!S.,!Hann,!B.,!Liu,!B.,!Park,!J.!W.,!Hong,!K.,!Benz,!C.!C.,!Marks,!J.!D.,!and!Kirpotin,! D.! B.! (2010)! Development! of! a! highly! stable! and! targetable!
! 95!
nanoliposomal! formulation! of! topotecan.! Journal# of# Controlled# Release! 141,!13D21.!
(27)! Yang,!T.,!Choi,!M.!K.,!Cui,!F.!D.,!Kim,!J.!S.,!Chung,!S.!J.,!Shim,!C.!K.,!and!Kim,!D.!D.!(2007)! Preparation! and! evaluation! of! paclitaxelDloaded! PEGylated!immunoliposome.!Journal#of#Controlled#Release!120,!169D177.!
(28)! Hong,!M.!H.,!Zhu,!S.! J.,! Jiang,!Y.!Y.,!Tang,!G.!T.,! and!Pei,!Y.!Y.! (2009)!Efficient!tumor! targeting! of! hydroxycamptothecin! loaded! PEGylated! niosomes!modified!with!transferrin.!Journal#of#Controlled#Release!133,!96D102.!
(29)! Cheng,! W.! W.! K.,! and! Allen,! T.! M.! (2008)! Targeted! delivery! of! antiDCD19!liposomal! doxorubicin! in! BDcell! lymphoma:! A! comparison! of! whole!monoclonal! antibody,! Fab'! fragments! and! single! chain! Fv.! Journal# of#
Controlled#Release!126,!50D58.!
(30)! Supko,! J.! G.,! and!Malspeis,! L.! (1993)! Pharmacokinetics! of! the! 9DAmino! and!10,11DMethylenedioxy!Derivatives!of!Camptothecin!in!Mice.!Cancer#Research!
53,!3062D3069.!
(31)! Gakhar,!G.,!WightDCarter,!M.,!Andrews,!G.,!Olson,!S.,!and!Nguyen,!T.!A.!(2009)!Hydronephrosis! and! urine! retention! in! estrogenDimplanted! athymic! nude!mice.!Veterinary#Pathology!46,!505D508.!
!
 
! 96!
 
 
 
 
 
 
 
 
Part II 
Targeted Delivery of siRNA 
 
 
 
 
 
 
 
 
 
 
! 97!
 
 
 
 
 
 
 
 
Chapter V 
Stability Optimization of CDP/siRNA Delivery System 
 
 
 
 
 
 
 
 
 
 
! 98!
5.1 Abstract  
siRNA holds great promise as a cancer therapeutic, however its delivery to the 
site of interest has proven to be challenging. In the past years, our research lab has 
developed a targeted nanoparticle delivery system for siRNA based on β-cyclodextrin-
containing polymers (CDP). The attachment of polyethylene glycol (PEG) onto the 
nanoparticles for steric stabilization is achieved via inclusion complex formation between 
adamantine (AD) and cyclodextrin cups in CDP using AD-PEG conjugate. This siRNA 
delivery system has shown to be effective in humans in a phase I trial. However, it 
demonstrates rapid clearance rate in in vivo. In this chapter, CDP/siRNA delivery system 
is further characterized and optimized for stability. The lessons learnt here will be used in 
the development of a new siRNA delivery system, MAD/siRNA. CDP/siRNA 
nanoparticles were observed by cryo-EM to be spherical and between 40 to 80 nm in size. 
5 kDa PEG chain lengths was found to be optimal for particle stability by salt stability 
studies in vitro. In vitro salt stability studies indicate that adding multivalently attached 
PEG (AD2-PEG and AD3-PEG) or lowering surface charge of nanoparticles (AD-Glu-
PEG and AD-Glu-Glu-PEG) was able to confer extra stability to the particles. In in vivo 
studies, particles stabilized with multivalently attached PEG resulted in prolonged 
circulation compared to other groups including naked siRNA and particles stabilized with 
AD-PEG, AD-Glu-PEG or AD-Glu-Glu-PEG. 
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5.2 Introduction  
The discovery of the RNA interference (RNAi) pathway by Fire and Mello (1) 
has led to great interest in its application in the field of cancer therapy due to its ability to 
trigger post-transcriptional sequence specific gene silencing. Central to this pathway is 
the small interfering RNA (siRNA) that can potentially cleave and degrade any mRNA 
sequence and thus eliminate its protein products.  
However, the delivery of intact and therapeutically significant amount of siRNA 
to the site of interest has proven to be challenging. Targeted delivery of siRNA via nano-
scaled vehicles holds great promise for cancer therapy due to its ability to (i) carry a large 
payload (siRNA), (ii) protect this payload from degradation, (iii) preferentially 
accumulate in tumor tissues via the enhanced permeability and retention (EPR) effect and 
(iv) enhance cellular uptake via targeting. 
In the past years, our research lab has developed a targeted nanoparticle delivery 
system for siRNA based on β-cyclodextrin-containing polymers (CDP), named CALAA-
01 (2, 3). CALAA-01 is composed of anionic siRNA condensed by cationic CDP to form 
nanoparticles via electrostatic interactions. The cationic CDP is formed by 
copolymerization of β-cyclodextrin with dimethylsuberimidate (DMS).  This nanoparticle 
is stabilized by the presence of a steric PEG layer on its surface. The attachment of 
polyethylene glycol (PEG) onto the nanoparticles is attained by the formation of an 
inclusion complex of adamantine (AD) with the cyclodextrin in the polymer via an AD-
PEG conjugate. Targeting is achieved by attaching ligands, such as human transferrin 
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protein on the distal end of AD-PEG conjugate to form AD-PEG-Transferrin (Scheme 
5.1). 
 
 
 
Scheme 5.1 Schematic of targeted siRNA delivery system CALAA-01. (A) Delivery 
components are β-cyclodextrin-containing polymer (CDP), adamantane polyethylene 
glycol conjugate (AD-PEG), and Transferrin targeting ligand conjugated to the distal end 
of PEG-AD (Tf-PEG-AD). (B) When the two vials are mixed together, the targeted 
nanoparticles form via self-assembly of the four components (4). 
best overall behavior is illustrated in Figure 4b, and its
relationship to the schematic in Figure 4a is provided.
Typically, these polycations have ∼5-6 repeating units (x
) 5, 6) and thus are low molecular weight polymers (can
be considered oligomers). This was accomplished by design
to provide low toxicity, minimal complement activation and
to permit renal clearance in animals and humans. The
structural variations investigated were (i) the type of cyclo-
dextrin (A in Figure 4),4,8,10,12 (ii) the absence of the
cyclodextrin (A in Figure 4) (other sugars4,8,12 and even
methylenes4,8,12 instead of sugars were explored), (iii) the
distance between the cyclodextrin and the charge center (S
in Figure 4),4,6,12 (iv) the type of charge center (C in Figure
4), for example, amidines, quarternary amines, and secondary
amines,4,9-12 and (v) the distance between the charge centers
(B in Figure 4).4,7 The structure-functional relationship
investigations primarily employed pDNA as the nucleic acid
being delivered. The overall conclusions obtained were (i)
the presence of the cyclodextrin gave the highest water
solubility and the lowest toxicity, (ii) the type of cyclodextrin
did not really affect the transfection properties (gene expres-
sion and toxicity) and beta-cyclodextrin was chosen because
it provided much better properties for large-scale processes
of collection and purification of the CDP over both alpha
and gamma cyclodextrin, (iii) when the distance between
the cyclodextrin and the charge center was small, the polymer
would not bind well to the nucleic acid (presumably due to
steric effects of the cyclodextrin), (iv) the further the distance
between the charge centers, the lower the cellular toxicity;
however, the binding to the nucleic acid also declined with
increasing distance, and (v) the amidine charge centers
provided for lower toxicity and better delivery efficacy.
Given these results, the CDP illustrated in Figure 4b provided
the best overall properties and was used as the polymer for
further formulations.
Nanoparticles formed from polymers and nucleic acids can
enter cells via endocytosis. In order to effectively deliver
the nucleic acid, the polymer must facilitate endocytic
pathway escape and release of the nucleic acid. Certain pH-
sensitive polymers such as polyethyleneimine (PEI) are said
Figure 2. Components and formulation of targeted nano-
particle-containing siRNA. (a) The delivery components
are (i) a water-soluble, linear cyclodextrin-containing poly-
mer (CDP), (ii) an adamantane (AD)-PEG conjugate (PEG
MW of 5000) (AD-PEG), a d (iii) the targeting component
that is an adamantane conjugate of PEG (PEG MW of
5000) that has human transferrin (Tf) conjugated at the
end opposite to the adamantane (Tf-PEG-AD). (b) The for-
mulation contains two vials, one with siRNA and the other
with the delivery compon nts. When the two vials are
mixed together, the targeted nanoparticles form via
self-assembly of the four components.
Figure 3. Schematic of how the targeted nanoparticles
function. (a) Nanoparticles are assembled from the four
components (see Figure 2). (b) Aqueous solutions of
nanoparticles are infused into patients. (c) The nano-
particles circulate in the blood of the patient and escape
via the “leaking” blood vessels in tumors. (d) Nano-
particles penetrate though the tumor and enter into cells
by receptor-mediated endocytosis (transmission elec-
tron micrograph of 50 nm nanoparticles entering a
cancer cell). Note that the nanoparticles enter and are
initially located in vesicles within the cell and must
escape and disassemble to deliver their payload. (e)
Targeted nanoparticles can have numerous interactions
(e.g., Tf with its receptor) on the surface of the cancer
cell that then stimulate entrance into the cell.
reviews DaVis
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This delivery system for siRNA has reached phase I clinical trial and evidence for 
sequence specific gene silencing has been shown (3). Yet this system has shown rapid 
clearance rate in in vivo imaging and in non-human primate pharmacokinetic studies (5, 
6) resulting in limited amount of nanoparticles reaching the solid tumor site via the EPR 
effect. This rapid clearance has been observed in other cationic polymer-based siRNA 
delivery systems (7, 8). The mechanisms of the fast clearance have been attributed to 
instability of the particles that lead to aggregation, as well as particle disassembly at the 
kidney site due to the presence of the negatively charged glomerular basement membrane 
resulting in competing electrostatic interactions (9). 
Before proceeding to develop another system for siRNA delivery, in this chapter, 
we attempt to further characterize and optimize this CDP/siRNA delivery system. This is 
done by understanding the particle morphology, the effect of PEG chain length and 
multivalency and particle surface charge on the particle stability and performance in both 
in vitro and in vivo conditions. The insights gained can be applied to the design of the 
new MAP/siRNA delivery system in the following chapter and to cationic polymer-based 
siRNA delivery systems in general. 
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5.3 Experimental  
5.3.1 General 
All commercially purchased reagents and solvents including anhydrous and 
HPLC grade were used without further purification. Discrete PEG chemicals were 
obtained from Quanta Biodesign (Powell, OH). Chemicals containing PEG longer than 1 
kDa were either purchased from JenKem Technology USA (Allen, TX) or from Laysan 
bio (Arab, AL). Female NCr nude mice were purchased from Taconic (Oxnard, CA). All 
other reagents were purchased from Sigma (St Louis, MO).  
1H and 13C spectra were recorded on either a 500 MHz or 600 MHz spectrometer 
(Inova, Varian). Mass spectrometry was carried out using a LCQ ion trap mass 
spectrometer (Finnigan, Thermo) by direct infusion electrospray ionization or MALDI-
TOF mass spectrometer (Voyager DETM-PRO, Applied Biosystems).  
Absorbance and fluorescence measurements were taken on a microplate reader 
(Infinite 200, Tecan). 
All animals were treated as per National Institute of Health Guidelines for Animal 
Care and approved by the California Institute of Technology Institutional Animal Care 
and Use Committee. 
 
5.3.2 Cryo-Electron Microscopy  
Cryo-electron microscopy (cryo-EM) was used to visualize nanoparticle 
morphology. Glow discharged Quantifoil holey carbon grid (SPI Supplies) was loaded 
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into an automated climate-controlled plunge-freezer (Vitrobot, FEI) and 3 µl of sample 
was applied. Grid was blotted, drained, plunged into liquid ethane, transferred and stored 
in liquid nitrogen. Samples were visualized under cryogenic temperatures with 
transmission electron microscope (Tecnai T12, FEI) equipped with a cryo-specimen 
holder. Acceleration voltage was set at 120 kV. 
 
5.3.3 Synthesis of AD-PEG with Different PEG Lengths  
100 mg (0.08 µM) of PEG1kDa and 68 mg (0.41 mM) of 
adamantanemethylamine were dissolved in 4 ml of DCM.  The reaction mixture was 
stirred for 4 h at room temperature before removing the solvent by rotary evaporator.  It 
was then reconstituted in water and centrifuged to remove any insoluble material.  The 
supernatant was recovered, filtered with a 0.2 µm filter (Amicon) and lyophilized to yield 
90 mg of product (87%). MALDI (m/z): 1264 [M+H].  Other PEG lengths, 2, 5 and 10 
kDa were synthesized in the same way. 
 
5.3.4 Synthesis of Multivalent AD-PEG  
1. AD-dPEG4-BOC 
315 mg (1.64 mM) of EDC and 16.7 mg (0.14 mM) of DMAP was added to 500 
mg (1.37 mM) of N-t-boc-amido-dPEG4-acid dissolved in 8 mL of anhydrous DCM in a 
25 mL 2-neck round bottom flask.  271 mg (1.64 mM) of adamantane methylamine 
dissolved in 2 mL of anhydrous DCM was then added and the reaction was stirred under 
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argon at room temperature overnight. The reaction mixture was concentrated on rotary 
evaporator and Prep TLC was run to isolate the desired product using DCM:MeOH 
(90:10) as the mobile phase. 550 mg of product was obtained after concentrating on 
rotary evaporator and drying in vacuum (78%). LC/MS (m/z): 513.3 [M+H]+. 
2. AD-dPEG-NH2 (HCl salt) 
3.2 mL of 6 N HCl in MeOH was added dropwise to 550 mg (1.07 mM) of AD-
dPEG4-BOC dissolved in 3.2 mL of MeOH.  This reaction was stirred for 6 h in an ice 
bath. Solvent and excess HCl was removed by rotary evaporator and dried under vacuum 
overnight to yield an amber colored viscous material (100%). 1H NMR ((CD3)2SO) δ 
7.90 (m, 2H), 7.63 (d, 1H), 3.40-3.69 (m, PEG Hs), 1.38-1.87 (m, AD Hs).  ESI/MS 
(m/z): 449.0 [M+Na]+. 
3. AD-Glu(Bn)-BOC 
300 mg (1.8 mM) of adamantane methylamine was dissolved in 4 mL of 
anhydrous DCM prior to the addition of 200 mg (0.46 mM) NHS-Glu(Bn)-BOC.  This 
mixture was allowed to react overnight at room temperature under constant stirring.  The 
desired product was isolated by running a flash column using DCM/methanol (98:2) as 
the mobile phase.  The product was concentrated and dried on rotary evaporator to yield a 
colorless viscous liquid (81%). 1H NMR ((CD3)2SO) δ 7.57 (m, 1H), 7.34 (m, 5H), 6.88 
(d, 2H), 5.06 (s, 2H), 4.40 (m, 1H), 1.35-1.87 (m, AD and BOC Hs). ESI/MS (m/z): 
507.3 [M+Na]+. 
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4. AD-Glu(Bn)-NH2 (TFA salt) 
4 mL of 25% of TFA/DCM was added dropwise to 180 mg (0.37 mM) of AD-
Glu(Bn)-BOC was dissolved in DCM.  This reaction was stirred for 6 h in an ice bath. 
Solvent and excess TFA was removed by rotary evaporator and dried under vacuum 
overnight to yield a viscous liquid (100%). 1H NMR ((CD3)2SO) δ 8.25 (m, 1H), 8.11 (s, 
2H) 7.34 (m, 5H), 5.09 (s, 2H), 4.40 (m, 1H), 1.35-1.87 (m, AD Hs).  ESI/MS (m/z): 
385.1 [M+H]+. 
5. AD-Glu(Bn)-PEG5kDa 
185 mg (0.37 mM) of AD-Glu(Bn)-NH2 (TFA salt) was dissolved in 6 mL of 
DCM.  100 µl of TEA and 500 mg (0.09 mM) of PEG5kDa-SCM was subsequently 
added and the reaction mixture was stirred overnight at room temperature.  Solvents were 
removed on rotary evaporator and vacuum prior to reconstituting the product in water. 
Insoluble material was filtered away with a 0.1µm PTFE syringe filter (Whatman).  The 
resultant solution was dialyzed against water 3 times using a 3 kDa MWCO centrifuge 
filter device (Amicon).  The product was lyophilized to give 413 mg of white fluffy 
powder (78%). 1H NMR ((CD3)2SO) δ 7.90 (m, 1H), 7.61 (d, 1H), 7.33 (m, 5H), 5.06 (s, 
2H), 4.40 (m, 1H), 3.23-3.69 (m, PEG Hs), 1.38-1.87 (m, AD Hs).  MALDI (m/z): 5900 
[M+H]+. 
6. AD-Glu-PEG5kDa 
To a 25 mL round bottom flask containing 6 mL of MeOH was charged 190 mg 
(0.03 mM) of AD-Glu(Bn)-PEG5kDa and 14 mg of Pearlman’s catalyst (20% 
Pd(OH)2/C).  Argon was used to vent the system of air prior to the insertion of a syringe 
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linked to a hydrogen filled balloon.  Argon was then flashed out with one balloon volume 
of hydrogen.  The reaction proceeded for 24 h under constant stirring and hydrogen 
balloon was refilled on demand.  Catalyst was filtered away from the reaction with a 0.1 
µm PTFE syringe filter prior to dialyzing with a 3 kDa MWCO centrifuge filter device 3 
times against water.  The product was then lyophilized to yield 150 mg of white fluffy 
material (82%). 1H NMR ((CD3)2SO) δ 7.90 (m, 1H), 7.61 (d, 1H), 4.40 (m, 1H), 3.23-
3.69 (m, PEG Hs), 1.38-1.87 (m, AD Hs).  MALDI (m/z): 5800 [M+H]+. 
7.  AD2-PEG5kDa  
150 mg (0.03mM) of AD-Glu-PEG5kDa was dried under vacuum for 3 h in a 25 
mL round bottom flask prior to the addition of 1 mL of anhydrous DCM.  22 mg (0.11 
mM) of EDC and 4.7 mg (0.03 mM) of DMAP were subsequently added followed by the 
addition of 46.5 mg (0.11 mM) of AD-dPEG4-NH2 (HCl salt) dissolved in 1 mL of 
anhydrous DCM and 40 µl TEA.  The reaction was stirred overnight under argon at room 
temperature.  Precipitate was filtered away using a 0.1 µm PTFE syringe filter.  Solvent 
was then removed via rotary evaporator and vacuum followed by reconstitution of the 
product in water.  Insoluble material was filtered away with a 0.1 µm PTFE syringe filter 
and the product was dialyzed against water 3 times using a 3kDa MWCO centrifuge filter 
device (Amicon).  The product was lyophilized to yield 148 mg of very light amber-
colored fluffy material (94%). 1H NMR ((CD3)2SO) δ 7.90 (m, 1H), 7.61 (d, 1H), 4.40 (m, 
1H), 3.23-3.69 (m, PEG Hs), 1.38-1.87 (m, AD Hs), 1.94x increase in Hs due to AD 
(from integration analysis). MALDI (m/z): 6150 [M+H]+. 
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5.3.5 Synthesis of Negatively Charged AD-PEG  
1. AD-Glu-PEG5kDa 
AD-Glu-PEG5kDa was synthesized as per section 6 under 5.3.2 Synthesis of 
multivalent AD-PEG. 
2. OH-Glu(Bn)-Glu(Bn)-BOC 
1.22 g (2.81 mM) of BOC-Glu(Bn)-NHS was added to 1 g (4.21 mM) of H-
Glu(Bn)-OH dissolved in 3.09 ml (28.1 mM) TEA and 42 ml of ACN/H2O (5:1).  This 
mixture was allowed to react overnight at room temperature under constant stirring.  
ACN and TEA were removed via rotary evaporator after which precipitation was 
observed.  Liquid-liquid extraction was performed with 3x 30 ml chloroform (with an 
additional 30 ml of water).  The organic phase was collected, dried with MgSO4, filtered, 
concentrated on rotary evaporator and dried under vacuum at 30 oC overnight to give a 
quantitative yield of white viscous liquid.  ESI/MS (m/z): 579.2 [M+Na]+. 
3. AD-Glu(Bn)-Glu(Bn)-BOC 
0.78 g (1.40 mM) of BOC-Glu(Bn)-Glu(Bn)-OH was dissolved in 5 ml of dry 
THF and transferred to a flask purged with and under Argon.  0.30 g (1.47mM) of DCC, 
0.23 g (1.40 mM) of adamantane methylamine and 0.20 g (1.47 mM) of HOBt in 0.49 ml 
(2.80 mM) of DIPEA each in 1 ml of dry THF were added to the above reaction under 
argon at 0 oC.  The reaction mixture was warmed to room temperature and reacted under 
constant stirring overnight.  Insoluble urea side product was filtered.  Filtrate was dried 
on rotary evaporator and crystallized with hot MeOH.  Crystals were grown for 24 h at 
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room temperature and consequently filtered and washed with cold MeOH to yield 0.42 g 
of white crystals (43%).  ESI/MS (m/z): 726.5 [M+Na]+. 
4. AD-Glu(Bn)-Glu(Bn)-NH2 (TFA salt) 
0.75 ml of TFA was added drop-wise to 150 mg (0.21 mM) of BOC-Glu(Bn)-
Glu(Bn)-AD dissolved in 2.25 ml of DCM at 0 oC.  Reaction was performed under 
constant stirring in ice bath for 5 h after which it was slowly warmed to room temperature, 
dried on rotary evaporator and under vacuum overnight to give quantitative yield of a 
clear viscous liquid. ESI/MS (m/z): 604.4 [M+H]+. 
5. AD-Glu(Bn)-Glu(Bn)-PEG5kDa 
102 mg (0.14 mM) of AD-Glu(Bn)-Glu(Bn)-NH2 was dissolved in 3 ml of dry 
DCM.  150 µl of TEA and 180 mg (0.04 mM) of NHS-PEG5kDa were subsequently 
added.  The reaction was stirred at room temperature overnight.  Solvent was removed on 
rotary evaporator and dried under vacuum overnight.  This was reconstituted in water, 
insoluble material was filtered via a 0.2 µm PVDF filter (Whatman) and the filtrate was 
dialyzed three times against water with a 3 kDa MWCO centrifuge filter device (Amicon). 
The supernatant was lyophilized to yield 158 mg of product (79%). 1H NMR ((CD3)2SO) 
δ 8.10 (m, 1H), 7.65-7.75 (d, 2H), 7.33 (m, 10H), 5.06 (s, 4H), 4.40 (m, 2H), 3.23-3.69 
(m, PEG Hs), 1.35-1.87 (m, AD Hs).  MALDI (m/z): 6400 [M+H]+. 
6. AD-Glu-Glu-PEG5kDa 
To a 25 mL round bottom flask containing 5 mL of MeOH was charged 150 mg 
(0.02 mM) of AD-Glu(Bn)-Glu(Bn)-PEG5kDa and 20 mg of Pearlman’s catalyst (20% 
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Pd(OH)2/C).  Argon was used to vent the system of oxygen prior to the insertion of a 
syringe linked to a hydrogen filled balloon.  Argon was then flashed out with one balloon 
volume of hydrogen.  The reaction proceeded for 24 h under constant stirring and 
hydrogen balloon was refilled on demand.  Catalyst was filtered away from the reaction 
with a 0.1 µm PTFE syringe filter prior to dialyzing with a 3 kDa MWCO centrifuge 
filter device (Amicon) 3 times against water.  The product was then lyophilized to yield 
121 mg of white fluffy material (83%). 1H NMR ((CD3)2SO) δ 8.10 (m, 1H), 7.65-7.75 (d, 
2H), 4.40 (m, 2H), 3.23-3.69 (m, PEG Hs), 1.35-1.87 (m, AD Hs).  MALDI (m/z): 6200 
[M+H]+. 
 
5.3.6 In Vitro and In Vivo Characterization  
1. Particle formulation  
A solution of AD-PEG was added to a solution of CDP at a 1:1 AD-PEG/β-CD 
(mol/mol) ratio in water.  This mixture was allowed to sit at room temperature for 30 min 
for the complexation of AD-PEG into β-cyclodextrin cups.  It was then added to an equal 
volume of siRNA in water at a charge ratio of 3 (+/-) (3 positive charges from CDP for 
every negative charge from siRNA) and mixed by pipetting.  After 30 min, tests and 
characterizations were performed. The formulations of particles stabilized with different 
PEG were conducted in the same manner. 
 
 
! 110!
2. Nanoparticle size and surface charge  
Particle size and zeta potential measurements were determined by dynamic light 
scattering (DLS) using a ZetaPALS instrument (Brookhaven Instruments, Holtsville, NY). 
Effective hydrodynamic diameter was recorded and averaged from 10 runs at 1 min each. 
Zeta potential measurements were collected for three sets of 10 runs at a target residual of 
0.012, and the results were averaged.  
3. Salt stability studies  
 Particle size was recorded for 5 runs at 1 min each on a DLS ZetaPALS 
instrument (Brookhaven Instruments, Holtsville, NY). Measurement was stopped to 
allow the addition of a 10x PBS solution to the particle formulation such that the 
resulting particle formulations contain 1x PBS.  Measurements were subsequently 
restarted and 10 successive runs of 1min each were recorded to study the effect of salt 
addition on particle stability.  
 To emulate PEG dissociation from nanoparticles, particle formulations were 
subjected to filtration with a 100 kDa MWCO (ca. 10 nm cut off) centrifuge membrane 
filter (Amicon) for 8 min at 2,000 g. Filtrations were performed for either 1, 4 or 12 times. 
Retentate was recovered, salt was added and any aggregation was tracked by DLS.  
4. Pharmacokinetic studies 
CDP/siRNA formulation was prepared at 1 mg siRNA/ml containing 20% siCy3 
(fluorescent siRNA) at charge ratio of 3 (+/-) and injected at 5 mg siRNA/kg mice.  To 
prepare for blood collection, hind legs of female BALC/c mice were shaved to expose the 
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saphenous veins.  Particle formulations were injected via tail vein. Time measurements 
began as soon as the injections were complete.  After 2 and 4 min, blood was collected 
from the saphenous vein into EDTA containing vials (Microvette CB 300 EDTA, 
Sarstedt).  Time points 7 and 9 min were collected from the alternate leg.  Samples were 
immediately centrifuged at 10,000 g, 4 oC for 15 min and supernatant removed and 
analyzed by measuring the fluorescence of siCy3 at 530 nm excitation and 570 nm 
emission wavelengths. Standard curves were generated from known concentrations of 
siCy3 in the same environment.   
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5.4 Results and Discussion 
5.4.1 Particle Morphology 
The CDP/siRNA delivery system has been well characterized (2).  However, no 
clear images of particle morphology were obtained.   
Transmission electron microscopy (TEM) was first used to visualize the 
nanoparticles.  Due to the low electron density of the constituents, uranyl acetate stain 
was added to assist in the visualization of the particles.  This negative heavy metal stain 
is designed to give more contrast to the image by staining the particle surroundings.  
However, the background appeared inhomogeneous and it was hard to distinguish 
between staining and drying effects from the nanoparticles.  As well, particle staining and 
drying is likely to affect the observed particle morphology.   
Therefore, cryo-electron microscopy (cryo-EM) was employed since it does not 
require sample staining or drying and thus is able to generate images of particle 
morphology in its natural environment. Figure 5.1A shows a representative cryo-EM 
image of CDP/siRNA/AD-PEG particle formulation. Particles are spherical discreet 
entities with diameters of between 40 to 80 nm.  This size correlates well with that 
determined from DLS measurements.  To further verify the particle structure, AD-PEG-
Au (5 nm gold particles, PEG length 1 kDa) was added to a formulation of 
CDP/siRNA/AD-PEG.  Figure 5.1B shows a particle surrounded with 5 nm Au 
nanoparticles. This indicates that some of the added AD-PEG-Au has displaced the AD-
PEG from the β-cyclodextrin cups on the surface of the particle.  These images serve as 
visual validation to our understanding of the structure of CDP/siRNA/AD-PEG particles. 
! 113!
 
Figure 5.1 Cryo-electron microscopy images of (A) CDP/siRNA/AD-PEG formulation at 
charge ratio 3 (+/-), (B) CDP/siRNA/AD-PEG formulation at charge ratio 3 (+/-) with 
added AD-PEG-Au.  
 
5.4.2 Effect of PEG Length Variation on Particle Stability  
AD-PEG is used for the stabilization of CDP/siRNA nanoparticles via surface 
steric hindrance effect.  Currently the system uses AD-PEG with PEG chain length of 5 
kDa.  No studies on whether additional PEG length may stabilize the particle further, or if 
shorter PEG lengths would be sufficient have been conducted. 
Hence, a series of AD-PEG at different PEG chain lengths were synthesized and 
the abilities of each in stabilizing CDP/siRNA nanoparticles at physiological salt 
concentrations were evaluated via a dynamic light scattering (DLS) based kinetic study.  
Figure 5.2 shows that in general, as PEG chain length increased, detectable aggregation 
decreased.  It is interesting to note however, that nanoparticles stabilized with PEG 
chains of 10 kDa showed slightly more aggregation than that stabilized with 5 kDa.  
Hence, PEG length of 5 kDa is verified to show the best salt stabilization performance 
and will continue to be used. 
A B 
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Figure 5.2 Salt stability of CDP/siRNA nanoparticles stabilized by PEG chains of 
various lengths. Formulated at charge ratio 3 (+/-), filtered once via 100 kDa membrane 
filter, 10x PBS was added at time 5 min such that the resulting solution was in 1x PBS. 
 
5.4.3 Effect of Multivalency and Surface Charge on Particle Stability  
Multivalent interactions have been shown to decrease dissociation constant, KD 
dramatically between targeting ligands and receptors (10, 11).  Therefore, multivalently 
attached PEG on CDP/siRNA nanoparticles through the non-covalent interactions 
between AD and β-cyclodextrin cups could also show a significant reduction in KD. A 
stronger binding between AD-PEG and CDP/siRNA nanoparticle would confer greater 
particle stability.  To achieve this, AD-PEG, AD2-PEG and AD3-PEG were synthesized 
and particles formulated with each were characterized by in vitro studies as well as by 
pharmacokinetic studies in mice.   
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As well, positively charged particles have been proven to trigger higher clearance 
rate than negatively charged particles. This is likely due to the presence of many 
negatively charged constituents in blood which the positively charged particles can bind 
to (12).  Zeta potential measurements of the current CDP/siRNA/AD-PEG system reveal 
particle surface charge of ca. 5 mV. This means that the particle surface is slightly 
positive.  To tune the surface charge to slightly negative, negatively charged groups can 
be incorporated into the AD-PEG constituent.  One such group is glutamate (Glu), which 
has an additional carboxylic acid side chain with a pKa of 4.1 and thus exists in its 
negatively charged form at physiological pH.  AD-PEG, AD-Glu-PEG and AD-Glu-Glu-
PEG were synthesized and particles formulated with each were characterized by in vitro 
and in vivo studies. 
 
 
Figure 5.3 Zeta potential and effective hydrodynamic diameter of CDP/siRNA 
nanoparticles stabilized by different PEG chains. Formulated at charge ratio of 3 (+/-), 
filtered via 100 kDa membrane filter; zeta potential (bar), effective diameter (scatter). 
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CDP/siRNA nanoparticles stabilized with no PEG, AD-PEG, AD2-PEG, AD3-
PEG, AD-Glu-PEG or AD-Glu-Glu-PEG were characterized for particle size and surface 
charge (Figure 5.3). It was found that without PEG, particle surface charge or zeta 
potential is at ca. 45 mV. When PEG was added, these particles exhibited a near neutral 
zeta potential.  This implies that the PEG layer effectively reduced the particle zeta 
potential by masking the surface charge.  The zeta potentials of CDP/siRNA 
nanoparticles stabilized with AD-Glu-PEG or AD-Glu-Glu-PEG were less than that with 
AD-PEG, AD2-PEG or AD3-PEG due to the negative charge present in AD-Glu-PEG and 
AD-Glu-Glu-PEG. The effective hydrodynamic diameters of particles stabilized with the 
different PEG chains were in the desirable sub 100 nm range. 
Particle stability in physiological salt conditions can be used as a prediction for its 
stability in vivo. Stable nanoparticles would remain as discreet entities while unstable 
nanoparticles would aggregate. In here, we use DLS as a guide for particle stability by 
measuring and recording any size changes after the addition of salt. CDP/siRNA 
nanoparticles are stabilized by the presence of a PEG layer on its surface, therefore, 
instability caused by the removal of this steric layer would lead to aggregations in salt 
conditions. The removal of this steric PEG layer was emulated by the filtration of 
CDP/siRNA nanoparticles. The molecular size cut off for the filter was chosen to be 100 
kDa, which is ca. 10 nm. This means that only unbound components including PEG, CDP 
or siRNA would flow through, while intact nanoparticles would remain in the retentate.  
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Figure 5.4 Salt stability of CDP/siRNA nanoparticles stabilized by different PEG chains. 
Formulated at charge ratio 3 (+/-), filtered via 100 kDa membrane filter, PBS was added 
at time 5 min such that the resulting solution was in 1x PBS. (A) After 1 filtration (B) 
After 4 filtrations (C) After 12 filtrations. 
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Figure 5.4 shows the effect of filtration on particle stability. After one filtration, 
all formulations containing PEG resulted in particle stabilization in salt conditions 
(Figure 5.4A). However, after 4 filtrations, formulations containing AD-PEG showed 
dramatic aggregation after salt addition, while formulations containing AD2-PEG, AD-
Glu-PEG, AD3-PEG and AD-Glu-Glu-PEG remained stable.  This implies that the 
amount of AD-PEG falling off the particle due to filtration exceeded that required for 
stabilization while sufficient amounts of AD2-PEG, AD-Glu-PEG, AD3-PEG or AD-Glu-
Glu-PEG remained on the surface of the nanoparticles.  After 12 filtrations, nanoparticles 
stabilized with AD2-PEG or AD3-PEG remained stable, particles stabilized with AD-Glu-
Glu were moderately stable, while all the others aggregated under salt conditions. 
Combined, these results indicate that multivalently attached PEG is capable of improving 
particle stability as observed for particles stabilized with AD2-PEG and AD3-PEG. As 
well, the addition of negative charge confers stability as seen for particles stabilized with 
AD-Glu-PEG and AD-Glu-Glu-PEG. 
From the encouraging salt stability results, pharmacokinetics of CDP/siRNA 
nanoparticles formulated with AD2-PEG, AD-Glu-PEG, AD3-PEG and AD-Glu-Glu-
PEG were evaluated in mice models and compared with that formulated with no PEG and 
with AD-PEG.  BALB/c mice were injected with particle formulations containing 20% 
siCy3 (fluorescently labeled siRNA) via tail vein injection and blood was collected from 
saphenous vein at various time points.  
Figure 5.5 shows the pharmacokinetic data for the nanoparticles stabilized with 
various PEG groups. Free siRNA, particles stabilized with AD-PEG, AD-Glu-PEG or 
AD-Glu-Glu-PEG all show similar fast in vivo circulation profiles. While particles 
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stabilized with AD2-PEG or AD3-PEG demonstrate dramatically longer in vivo 
circulation profiles. After 10 min of injection, the fraction of siCy3 remaining in blood in 
formulations containing AD2-PEG or AD3-PEG were over ten times greater than that 
with no PEG, with AD-PEG, AD-Glu-PEG or AD-Glu-Glu-PEG.  It is interesting to note 
that although particles stabilized with AD-Glu-Glu-PEG showed good stability in in vitro 
conditions, in in vivo, the effect of this extra stability was not observed. This is perhaps 
because the strength of binding between PEG onto cyclodextrin cups is more important 
than having a more negative charge on the surface of the nanoparticles for longer 
circulations in vivo.  
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Figure 5.5 Pharmacokinetics of CDP/siRNA nanoparticles stabilized with different PEG 
chains in BALB/c mice. Formulated with 20% siCy3, charge ratio 3(+/-), 5 mg siRNA/kg 
mouse injection, dashed lines join data for each individual mouse. 
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5.5 Conclusions  
In this chapter, the current siRNA delivery system developed by the Davis lab 
was further characterized and optimized. First, particle morphology was observed by 
cryo-EM to show that particles are between 40 to 80 nm in size. PEG compounds capable 
of multivalent attachment onto cyclodextrin cups (AD2-PEG and AD3-PEG) and capable 
of lowering the zeta potential of the nanoparticle system (AD-Glu-PEG and AD-Glu-Glu-
PEG) were synthesized. In vitro salt stability studies indicate that adding multivalently 
attached PEG or lowering surface charge of the nanoparticles were capable of conferring 
extra stability. In pharmacokinetic studies, particles stabilized with multivalently attached 
PEG demonstrated prolonged in vivo circulation compared to all other groups including 
particles with a more negative charge.  
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6.1 Abstract  
The use of siRNA as a cancer therapeutic possesses great potential. However, the 
delivery of sufficient amount of therapeutically active siRNA to the solid tumor site has 
proven to be challenging. Our lab has developed a siRNA delivery system based on 
cyclodextrin-containing polymers named CALAA-01. This has shown effectiveness in 
clinical trials, yet, it suffers from its fast in vivo clearance. In here, a new delivery 
platform involving boronic acid-diol complexation is used for siRNA delivery. A 
copolymer of mucic acid and dimethylsuberimidate (DMS), named MAD was 
synthesized and used to condense the anionic siRNA into nanoparticles. The condensed 
nanoparticles were stabilized by placing a PEG layer onto the particle surface using 
boronic acid-diol complexation where boronic acid PEG (BA-PEG) form reversible 
covalent bonding with vicinal diol groups on the MAD backbone. Targeting was 
achieved by conjugating the distal end of the BA-PEG with a targeting agent, in this case, 
a Herceptin antibody. Through transfection studies, MAD/siRNA nanoparticles were 
found to effectively enter cells and demonstrate low cellular toxicity. It was seen by gel 
electrophoresis studies that charge ratios of 1.5 (+/-) for MAD-2 and MAD-4 were 
sufficient to encapsulate all siRNA. Different BA-PEG were synthesized and tested for 
their effectiveness in stabilization of the MAD/siRNA nanoparticles. It was found that 
nitroPBA-PEG provided the most stabilization. MAD/siRNA nanoparticles stabilized 
with nitroPBA-PEG show a diameter of ca. 130 nm and a surface charge of ca. -4 mV. 
Pharmacokinetic studies in mice demonstrate improved circulation compared to CALAA-
01.  
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6.2 Introduction 
 In the past years, our research group has been involved in translating a polymer-
based nanoparticle delivery system for siRNA from the lab to the clinic, named CALAA-
01 (1, 2). CALAA-01 is comprised of anionic siRNA condensed by cationic β-
cyclodextrin-containing polymers (CDP) to form a nanoparticle. This nanoparticle is 
stabilized by a steric polyethylene glycol (PEG) layer and targeted with a human protein 
transferrin. In phase I studies, evidence for sequence specific gene silencing has been 
shown (1). However, this system (3, 4), like many other cationic polymer-based siRNA 
delivery systems (5, 6), shows rapid clearance in vivo. It is proposed that particle stability 
and particle surface charge are the main contributors to this issue.   
  We have created a new targeted nanoparticle delivery platform involving the use 
of boronic acid-diol complexation that can be applied to siRNA delivery and potentially 
prolong its circulation in vivo. 
  We designed the cationic siRNA condensing polymer to be a copolymer of mucic 
acid and dimethylsuberimidate (DMS), named MAD. Mucic acid, the oxidized form of 
galactose was selected due to its polyol characteristic and economic reasons. DMS was 
chosen due to the finding in CDP/siRNA delivery system that it provided the optimal 
distance between charge centers for transfection efficiency and cell viability (7).  The 
condensed MAD/siRNA nanoparticles are stabilized by placing a PEG layer onto the 
particle surface using boronic acid-diol complexation where boronic acid PEG (BA-PEG) 
form reversible covalent bonding with vicinal diol groups on the MAD backbone. 
Targeting is achieved by conjugating the distal end of the BA-PEG with a targeting agent 
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of choice, for instance, an antibody (Scheme 6.1). 
 
  
Scheme 6.1 Targeted MAD/siRNA nanoparticle delivery system assembly. MAD, 
copolymer of mucic acid and polyethylene glycol; (MAD-2 is shown, two methylene 
units between charge center (amidine) and binding site (polyol)); BA, boronic acid.  
 
The negative charge resulting from boronic acid binding to polyols would bring 
the particle to a slightly negative surface charge regime. This will minimize electrostatic 
interactions with blood components and reduce the recognition and clearance by the 
mononuclear phagocyte system (MPS) (8). Hence, this siRNA delivery system could 
potentially show longer in vivo circulation. As well, the synthesis of MAD is 
straightforward compared to that of CDP. This is more favorable from both research and 
possible future clinical viewpoints. In addition, the presence of boron leads to the 
potential for imaging, such as, neutron capture autoradiography using the natural high 
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abundance of B-10 isotope (19.9%) that is capable of capturing neutrons (9-11). Boron 
neutron capture therapy (BNCT) for solid tumors is also possible. This is where solid 
tumors containing accumulated boron are irradiated with low-energy neutrons (12, 13) to 
generate high energy radiation that in turn destroys the tumor cells (14). 
In this chapter, the new MAD/siRNA delivery system was designed, synthesized 
and characterized. It was evaluated by in vitro studies including siRNA encapsulation 
efficiency via gel electrophoresis, cellular transfection and cell viability. It was also 
characterized by pharmacokinetic studies in mice.  
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6.3 Experimental  
6.3.1 General 
All commercially purchased reagents and solvents including anhydrous and 
HPLC grade were used without further purification. Dimethylsuberimidate (DMS) was 
obtained from Thermo Scientific (Rockford, IL). 3-carboxylphenylboronic acid and 3-
carboxy 5-nitrophenylboronic acid were purchased from Alfa Aesar (Ward Hill, MA). 
Amine polyethylene glycol carboxylic acid (NH2-PEG-CO2H, MW 5000) was purchased 
from JenKem Technology USA (Allen, TX). Herceptin® (Trastuzumab) was obtained 
from Dr. Y. Yen at the City of Hope (Duarte, CA). All other reagents were purchased 
from Sigma (St Louis, MO).  
1H and 13C NMR spectra were recorded on either a 500 MHz or 600 MHz 
spectrometer (Inova, Varian). Mass spectrometry was carried out using a LCQ ion trap 
mass spectrometer (Finnigan, Thermo) by direct infusion electrospray ionization or 
MALDI-TOF mass spectrometer (Voyager DETM-PRO, Applied Biosystems).  
Absorbance and fluorescence measurements were taken on a microplate reader 
(Infinite 200, Tecan). 
 
6.3.2 Synthesis of MAD (Mucic Acid and DMS Copolymer)  
1. Mucic acid dimethyl ester 
120 ml of methanol and 0.4 ml of concentrated sulfuric acid were added to 5 g 
(22.8 mmol) of mucic acid.  This mixture was refluxed at 85 oC overnight under constant 
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stirring.  Solids were filtered, washed with methanol, recrystallized and dried under 
vacuum overnight to yield 8 g (71%) of mucic acid dimethyl ester. 1H NMR ((CD3)2SO) 
δ 4.88-4.91 (d, 2H), 4.78-4.81 (m, 2H), 4.28-4.31 (d, 2H), 3.77-3.78 (d, 2H), 3.63 (s, 6H).  
ESI/MS (m/z): 261.0 [M+Na]+. 
2. Protected mucic acid diamine (with 2 methylene units) 
60 ml of methanol, 5.25 g (32.7 mmol) of N-Boc-ethylenediamine and 5.7 ml 
(32.7 mmol) of N, N-diisopropylethylamine (DIPEA) were added to 3 g (12.6 mmol) of 
mucic acid dimethyl ester. This reaction mixture was refluxed at 85 oC overnight under 
constant stirring. Solids were filtered, washed with methanol, recrystallized and dried 
under vacuum to give 4.65 g (75%) of product.   1H NMR ((CD3)2SO) δ 7.72 (t, 2H), 6.82 
(t, 2H), 5.13-5.15 (d, 2H), 4.35-4.38 (d, 2H), 4.08-4.11 (d, 2H), 3.78-3.80 (d, 2H), 2.95-
3.15 (m, 8H), 1.36 (s, 18).  ESI/MS (m/z): 517.1 [M+Na]+. 
3. Mucic acid diamine (with 2 methylene units) 
8 g (16.2 mmol) of protected mucic acid diamine was transferred to a flask 
containing 3 N HCl in methanol (160 ml) and reacted for 6 h at room temperature under 
constant stirring.  Precipitate was filtered, washed with methanol and vacuum dried 
overnight to yield 5.69 g (96%) of mucic acid diamine. 1H NMR ((CD3)2SO) δ 7.93-7.99 
(m, 8H), 5.31-5.34 (d, 2H), 4.57 (d, 2H), 4.10-4.17 (d, 2H), 3.82 (d, 2H), 3.32-3.38 (m, 
4H), 2.82-2.86 (m, 4H).  ESI/MS (m/z): 295.1 [M]+. 
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4. MAD-2 (Mucic Acid DMS copolymer, with 2 methylene units) 
To a 1.5 ml Eppendorf tube containing 85.5 mg (0.233 mmol) of mucic acid 
diamine in 0.8 ml of 0.5 M NaHCO3 was added 63.3 mg (0.233 mmol) of 
dimethylsuberimidate (DMS). Components were dissolved by vortexing and centrifuging.  
The resulting mixture was stirred at room temperature for 15 h.  8 ml of water was added 
and the pH brought to 4 with 1 N HCl.  This solution was then dialyzed against water 
with a 3 kDa MWCO membrane filter device (Amicon) until a constant pH was attained. 
The supernatant was filtered with a 0.2 µm filter (Acrodisc) and lyophilized to yield 49 
mg (33%) of white fluffy powder.  1H NMR ((CD3)2SO) δ 9.15, 7.92, 5.40, 4.55, 4.16, 
3.82, 3.38, 3.29, 2.37, 1.59, 1.28. 13C NMR ((CD3)2SO) δ 174.88, 168.38, 71.45, 71.22, 
42.34, 36.96, 32.74, 28.09, 26.90. GPC Mw = 6800, Mw/Mn = 1.14. 
5. MAD-x (Mucic Acid DMS copolymer, with x methylene units) 
To synthesize MAD with different number of methylene units between charge 
center (amidine) and binding site (polyol), alternatives to N-Boc-ethylenediamine were 
used in section 2. For example, to make MAD-4, N-Boc-butanediamine was used in the 
reaction. These reactions were conducted in the same manner as for the synthesis of 
MAD-2. 
6. Absolute molecular weight determination of MAD 
The absolute determination of molecular weights does not require standards for 
calibration. This was determined on a GPC system equipped with an Agilent pump, 
degasser and autosampler, a gel permeation column (TSKgel G3000PWxl-cationic 
polymer column, Tosoh) connected to a multi-angle laser light scattering (MALS) 
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detector (DAWN HELEOS, Wyatt) and a refractive index (RI) detector (Optilab rEX, 
Wyatt). 0.1 M NaNO3 was used as the eluent at a flow rate of 0.7 ml/min. Specific 
refractive increment, dn/dc was measured by batch injection of various concentrations of 
MAD dissolved in PBS into Optilab rEX at 0.2 ml/min. 
 
6.3.3 Synthesis of Boronic Acid PEG Linker 
1. PBA-PEG-CO2H (3-amide-PEG5kDa-carboxylic acid phenylboronic acid) and PBA-
PEG 
To 200 mg (1.21 mM) of 3-carboxyphenylboronic acid dissolved in 5 ml of 
anhydrous tetrahydrofuran was added 18.7 µl (0.24 mM) of anhydrous 
dimethylformamide under argon. This reaction vessel was transferred into an ice bath and 
195 µl (2.89 mM) of oxalyl chloride was slowly added under argon. Reaction was 
allowed to proceed under vent and constant stirring for 2 h at room temperature. Solvent 
and excess reagent were removed under vacuum. 37 mg (0.2 mM) of this dried acyl 
chloride compound was dissolved in 15 ml of anhydrous dichloromethane under argon. 
To this was added 500 mg (0.1 mM) of NH2-PEG5kDa-CO2H and 52 µl (0.3 mM) of dry 
DIPEA under argon. After overnight reaction under constant stirring, solvent was 
removed under vacuum and the dried product was reconstituted in 0.5 N HCl. This 
solution was passed through a 0.2 µm filter (Acrodisc) and dialyzed against water with a 
3 kDa MWCO membrane filter device (Amicon) until constant pH was attained. The 
supernatant was then filtered with a 0.2 µm filter (Acrodisc) and lyophilized to yield 377 
mg (73%) of PBA-PEG-CO2H. 1H NMR ((CD3)2SO) δ 12.52 (s, 1H), 8.39 (t, 1H), 8.22 (s, 
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1H), 8.14 (s, 2H), 7.88 (d, 1H), 7.82 (d, 1H), 7.39 (t, 1H), 3.99 (s, 2H),  3.35-3.62 (PEG 
peak). MALDI-TOF (m/z): 5600 g/mol (NH2-PEG5kDa-CO2H, 5400 g/mol). The 
synthesis of PBA-PEG proceeded in the same way except NH2-PEG5kDa-methoxy was 
used. 
2. nitroPBA-PEG-CO2H (3-amide-PEG5kDa-carboxylic acid, 5-nitrophenylboronic 
acid) and nitro-PEG 
Synthesis of nitroPBA-PEG-CO2H was performed in the same way as for PBA-
PEG-CO2H except the starting material was 3-carboxy 5-nitrophenylboronic acid. The 
reaction yielded 393 mg (76%) of nitroPBA-PEG-CO2H. 1H NMR ((CD3)2SO) δ 12.52 (s, 
1H), 8.89 (t, 1H), 8.72 (s, 1H), 8.68 (s, 1H), 8.64 (s, 1H), 8.61 (s, 2H), 3.99 (s, 2H),  3.35-
3.62 (PEG peak). MALDI-TOF (m/z): 5600 g/mol (NH2-PEG5kDa-CO2H, 5400 g/mol). 
The synthesis of nitroPBA-PEG proceeded in the same way except NH2-PEG5kDa-
methoxy was used. 
3. pKa determination for PBA 
pKa of PBA was found by measuring the change in absorbance of PBA as it 
converted from trigonal (in low pH) to tetrahedral (in high pH) conformation. To a 
solution of 10-3 M PBA in 0.1 M PBS, pH 7.4 was titrated 1 N NaOH. pH was recorded 
and corresponding samples were removed for absorbance measurements at 268 nm. 
4. Herceptin-PEG-nitroPBA (Herceptin-PEG5kDa-5-nitrophenylboronic acid) 
36 mg (6.4 µM) of nitroPBA-PEG-CO2H, 12.3 mg (64 µM) of EDC and 11.1 mg 
(96 µM) of NHS were dissolved in 2.4 ml of 0.1 M MES buffer, pH 6.0. This mixture 
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was reacted for 15 min on a rotating shaker at room temperature. Excess reactants were 
dialyzed away with 3 kDa MWCO membrane filter device (Amicon). This activated 
carboxylic acid PEG compound was added to 20 mg (0.14 mM) of Herceptin in 0.1 M 
PBS, pH 7.2. Reaction was carried out on a rotating shaker at room temperature for 2 h 
and then dialyzed 4 times with 50 kDa MWCO membrane filter device (Amicon) against 
1x PBS at pH 7.4. MALDI-TOF: average conjugation of 1 to 2 nitroPBA-PEG per 
antibody.  
 
6.3.4 In Vitro Characterization 
1. Particle formulation (without PEG) 
A solution of MAD was added to a solution of siRNA at a charge ratio of 3 (+/-) 
(three positive charge from MAD for every negative charge from siRNA) in water and 
mixed by pipetting.  This mixture was allowed to sit at room temperature for 10 min 
before characterizations were performed. Particle formulations containing MAD-2, 
MAD-4 or MAD-6 and at different charge ratios were conducted in the same manner. 
2. Agarose gel mobility studies 
  1 w% of agarose gel was made by dissolving 0.5 g of agarose powder in 50 ml of 
0.5x TBE buffer.  After the addition of 10 µl of ethidium bromide dye, the mixture was 
heated thoroughly and poured into a cast to set.  Particle formulations mixed with loading 
dye were loaded into the wells.  Voltage was applied and the positions of nucleic acids 
within the wells were visualized under ultraviolet light due to the specific ethidium 
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bromide binding to nucleic acids.  Since the charge from free nucleic acids (anionic) and 
that from nucleic acids encapsulated by cationic polymers (near neutral) are different, 
therefore, relative quantification of the nucleic acid encapsulation capacity of polymers at 
different charge ratios is possible. 
3. In vitro transfection 
For the transfection of MAD/pDNA nanoparticles into HeLa cells, HeLa cells 
were seeded at 20,000 cells/well in 24 well plates 48 h prior to transfection and grown in 
medium supplemented with 10 % fetal bovine serum (FBS).  MAD particles were 
formulated to contain 1 µg of pGL3 in 200 µl of Opti-MEM I at various charge ratios of 
polymer to pDNA.  Growth medium was removed, cells washed with PBS and the above 
particle formulation added.  The cells were incubated at 37 oC and 5% CO2 for 5 h before 
the addition of 800 µl of growth medium supplemented with 10% FBS.  48 h of 
incubation later, a fraction of the cells were analyzed for cell viability using MTS assay.  
The remaining cells were lysed in 100 µl of 1x Luciferase Cell Culture Lysis Reagent.  
Luciferase activity was determined by adding 100 µl of Luciferase Assay Reagent to 10 
µl of cell lysate and the bioluminescence was quantified using a Monolight luminometer.   
Luciferase activity was subsequently reported as relative light units (RLU) per 10,000 
cells.  
For the cotransfection of MAD/pDNA and/or siRNA particles into HeLa Cells, 
HeLa cells were seeded at 20,000 cells/well in 24 well plates 48 h prior to transfection 
and grown in medium supplemented with 10% FBS.  MAD particles were formulated to 
contain 1 µg of pGL3 and 50 nM of siGL3 in 200 µl of Opti-MEM I at a charge ratio of 5 
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(+/-).  Particles containing only pGL3 or pGL3 and siCON were used as controls.  
Growth medium was removed, cells washed with PBS and the above particle formulation 
added.  Cells were subsequently incubated at 37 oC and 5% CO2 for 5 h before the 
addition of 800 µl of growth medium supplemented with 10% FBS.  48 h of incubation 
later, cells for assayed for viability and luciferase activity (as above). 
For the transfection of MAP/siGL3 into HeLa-LUC cells, HeLa-LUC, cells 
(containing the gene for firefly luciferase protein) were seeded at 20,000 cells/well in 24 
well plates 48 h prior to transfection and grown in medium supplemented with 10% FBS.  
MAD particles were formulated to contain 0, 50 and 100 nM of siGL3 in 200 µl of Opti-
MEM I at a charge ratio of 5 (+/-).  Particles containing only pGL3 or pGL3 and siCON 
were used as controls.  Growth medium was removed, cells washed with PBS and the 
above particle formulation added.  The cells were subsequently incubated at 37 oC and 
5% CO2 for 5 h before the addition of 800 µl of growth medium supplemented with 10% 
FBS.  48 h of incubation later, cells for assayed for viability and luciferase activity (as 
above). 
4. Particle formulation (with PEG)  
A solution of PBA-PEG was added to a solution of MAD at 3 (+/-) charge ratio 
(three positive charge from MAD for every negative charge from siRNA) in phosphate 
buffer at pH 7.4.  This mixture was allowed to sit at room temperature for 10 min for the 
complexation of PBA-PEG with the diol-containing MAD.  This was then added to an 
equal volume of siRNA in water and mixed by pipetting. After 10 min, characterizations 
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were performed. The formulations of particles stabilized with nitroPBA-PEG and at 
different charge ratios were conducted in the same manner. 
5. Nanoparticle size and surface charge  
Particle size and zeta potential measurements were determined by dynamic light 
scattering (DLS) using a ZetaPALS instrument (Brookhaven Instruments, Holtsville, NY). 
Effective hydrodynamic diameter was recorded and averaged from 10 runs at 1 min each. 
Zeta potential measurements were collected for three sets of 10 runs at a target residual of 
0.012, and the results were averaged.  
6. Salt Stability Studies  
Particle size was recorded for 5 runs at 1 min each on a DLS ZetaPALS 
instrument (Brookhaven Instruments, Holtsville, NY). Measurement was stopped to 
allow the addition of a 10x PBS solution to the particle formulation such that the 
resulting particle formulations contain 1x PBS.  Measurements were subsequently 
restarted and 10 successive runs of 1 min each were recorded to study the effect of salt 
addition on particle stability.  
 
6.3.5 In Vivo Characterization 
1. Pharmacokinetic Studies 
MAD/siRNA nanoparticles stabilized with nitroPBA-PEG was prepared at 1 mg 
siRNA/ml containing 20% siCy3 (fluorescent siRNA) in 0.9 wt% NaCl at a charge ratio 
of 3 (+/-) and injected at 5 mg siRNA/kg mice into female BALB/c mice.  To prepare for 
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blood collection, hind legs of mice were shaved to expose the saphenous veins.  Particle 
formulations were injected via tail vein. Time measurement began as soon as the 
injection was complete.  After 2 and 4 min, blood was collected from the saphenous vein 
into EDTA containing vials (Microvette CB 300 EDTA, Sarstedt).  Time points 7 and 9 
min were collected from the alternate leg.  Samples were immediately centrifuged at 
10,000 g, 4 oC for 15 min and supernatant removed and analyzed by measuring the 
fluorescence of siCy3 at 530 nm excitation and 570 nm emission wavelengths. Standard 
curves were generated from known concentrations of siCy3 in the same environment.   
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6.4 Results and Discussion 
6.4.1 Synthesis of MAD (Mucic Acid and DMS Copolymer)  
 
 
Scheme 6.2 Synthesis of MAD-2 (copolymer of mucic acid and DMS, with 2 methylene 
units between charge center and binding site). 
 
The synthesis methodology for MAD is outlined in Scheme 6.2.  Mucic acid was 
modified to contain reactive methyl ester groups on both ends, this was then conjugated 
with either N-boc-ethylenediamine, N-boc-butanediamine, or N-boc-hexanediamine to 
form mucic acid containing either 2, 4 or 6 methylene groups between the charge center 
(amidine) and the binding site (polyol) respectively (Scheme 6.3). Mucic acid diamine 
was then polymerized with DMS to form MAD. Any unreacted reagents were removed 
by dialysis. The synthesis for MAD was straightforward and no difficulties were 
encountered. Figure 6.1 shows a representative proton NMR for MAD. 
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Scheme 6.3 Synthesis of MAD-x (copolymer of mucic acid and DMS), where x is 
number of methylene units separating binding site and charge center. 
   
 
Figure 6.1 1H spectrum of MAD-6 in DMSO-d6.  
The absolute molecular weights of MAD were measured using multi-angle laser 
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increment (dn/dc) value of 0.169 ml/g was found for the MAD-2. This dn/dc value along 
with MALS and RI data were used to determine the number average molecular weight 
(Mn), weight average molecular weight (Mw) and polydispersity (Mw/Mn) of MAP 
(Table 6.1).  
 
 
Table 6.1 Characterization of MAD. MAD-x, x represent number of methylene groups; 
Average molecular weight determined as (Mw+Mn)/2; Mw, weight average molecular 
weight; Mn, number average molecular weight. Polydispersity determined as Mw/Mn. 
 
6.4.2 Synthesis of Boronic Acid PEG Linker 
This is similar to that in chapter II, section 2.4.2. 
Briefly, to prepare a stabilized and targeted nanoparticle, the covalent, reversible 
binding property between boronic acids and MAD (diol-containing) was used. The pKa 
of phenylboronic acid (PBA) is high at 8.8. To decrease the pKa, PBAs with electron 
withdrawing groups on the phenyl ring were employed to increase the acidity of the 
boron atom. Commercially available 3-carboxyPBA and 3-carboxy 5-nitroPBA were 
converted into acyl chlorides using oxalyl chloride (Scheme 6.4). These acyl chloride 
species were then reacted with NH2-PEG to form PBA-PEG and nitroPBA-PEG 
respectively. The addition of bases DMF and DIPEA were required for the synthesis 
Mw (Da) Mn (Da) Polydispersity Ave Molecular Weight # of repeats
MAD-2 6804 5962 1.14 6.4 kDa 11-13
MAD-4 6982 6174 1.13 6.6 kDa 11-13
MAD-6 8086 7373 1.1 7.7 kDa 12-13
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reactions to proceed. However, the presence of these bases resulted in tetrahedral adduct 
formations with acidic PBA. To remove these adducts, work up in 0.5 N HCl with 
subsequent equilibration to neutral pH by dialysis against water was carried out. 
 
 
Scheme 6.4 Synthesis of PBA-PEG and nitroPBA-PEG.  
 
pKa values of the modified PBAs were determined by absorbance changes due to 
conformational change of PBA from trigonal to tetrahedral form as pH increased (Table 
6.2). PBA with electron withdrawing groups resulted in lower pKa’s, with nitroPBA-PEG 
having the lowest pKa of 6.8. Thus, at physiological pH, most of the PBA was present in 
the reactive anionic tetrahedral form. Because of the low pKa value for nitroPBA-PEG, it 
was chosen to stabilize the MAD/siRNA nanoparticles. 
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Table 6.2 pKa values of different PBAs (phenylboronic acids).  
 
Targeting is achieved by conjugating Herceptin to nitroPBA-PEG-CO2H via EDC 
coupling (Scheme 6.5). An average of 1 to 2 PEGs were attached per Herceptin antibody. 
 
Scheme 6.5 Synthesis of Herceptin-PEG-nitroPBA.  
 
6.4.3 In Vitro Characterization 
Gel electrophoresis was used to evaluate the siRNA encapsulation capabilities of 
MAD. Free siRNA (anionic) would travel towards the cathode, while encapsulated 
siRNA (near neutral) would remain in the wells. Figure 6.2 shows the siRNA 
encapsulation abilities of MAD-2, MAD-4 and MAD-6 at various charge ratios. For 
MAD-2 and MAD-4, charge ratios of 1.5 (+/-) were sufficient to encapsulate all the 
siRNA, while for MAD-6, a higher charge ratio of 3 (+/-) was required. Therefore, we 
choose MAD-2 and MAD-4 to advance to further testings. It is noted that for CDP, the 
siRNA condensing polymer in CALAA-01, full siRNA encapsulation was observed at 
charge ratio of 3 (+/-) (15). 
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Figure 6.2 Electrophoretic gel mobility shift assay for MAD/siRNA. siRNA condensed 
with (A) MAD-2 (B) MAD-4 or (C) MAD-6. From left to right, 100 bp ladder, free 
siRNA, particles formulated at 0.5, 1, 1.5, 2, 2.5, 3, 4 and 5 (+/-) charge ratios. 
 
 
100bp  0  0.5   1  1.5   2   2.5    3    4    5  
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To test the efficiency and toxicity of MAD for the transfection of nucleic acids 
into cells, pGL3, a plasmid containing the firefly luciferase gene was condensed by MAD 
at various charge ratios and transfected into HeLa cells, a cell line capable of translating 
pGL3 into the luminescent luciferase protein. Figure 6.3 illustrates the resultant luciferase 
protein activity and cell viability.  There were greater than 2 orders of magnitude 
increases in luciferase activity when charge ratios of between 1.5 and 10 (+/-) were used 
compared to the control.  This result suggests that MAD is capable of delivering nucleic 
acids into cells.  Cell viability is good for charge ratios of up to 5 (+/-) indicating that 
MAD is relatively non-toxic to the cells. 
 
 
Figure 6.3 Transfection of MAD-2/pGL3 into HeLa cells at various charge ratios; 
relative light units (RLU) per 10,000 cells (bar), fraction of cell survival (scatter).  
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In order to assess the ability of MAD in delivering siRNA, cotransfection of 
pGL3 and siGL3 into HeLa cells was conducted to see any silencing of luciferase gene 
induced by siGL3.  pGL3 or pGL3 and control siRNA (siCON) serve as controls for this 
study.  Figure 6.4 indicate that the cotransfection of pGL3 and siGL3 resulted in nearly 
50% reduction in luciferase signal.  This suggests that pGL3 and siGL3 are co-delivered 
into the cell. 
 
Figure 6.4 Cotransfection of pGL3 and siGL3 by MAD-2 into HeLa cells. 
 
Another transfection method to evaluate the capability of MAD in delivering 
siRNA into cells is the transfection of siGL3 into HeLa-LUC cells, a cell containing the 
gene for luciferase protein.  From Figure 6.5, it can be seen that with increasing siGL3 
concentration, the luciferase activities were reduced. This suggests knockdown of 
luciferase gene by siGL3 and thus indicates that siGL3 has been successfully delivered 
internally into the cell. 
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Figure 6.5 Transfection of MAD-2/siGL3 at various concentrations into HeLa-LUC cells.  
 
Now that we have shown that MAD is capable of siRNA encapsulation at low 
charge ratios and demonstrate good transfection and low cellular toxicity, we proceed to 
add BA-PEG to form stabilized nanoparticles. 
The effect of PBA-PEG and nitroPBA-PEG on nanoparticle formation and 
stability were examined. The use of PBA-PEG formed MAD/siRNA particles of 150-300 
nm in size. MAD-4 resulted in smaller nanoparticles than when MAD-2 was used. 
However, upon the addition of salt, all particles aggregated indicating that PBA-PEG was 
incapable of providing sufficient stability to the nanoparticles. When nitroPBA-PEG was 
used, particles at all charge ratios tested, 1 and 3 (+/-), demonstrated stabilized 
nanoparticles in salt conditions. The difference in particle stability conferred by PBA-
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PEG and nitroPBA-PEG indicates the importance of the modification of boronic acid to 
possess stronger binding to polyols.  
For siRNA condensed with MAD-4 without the presence of stabilizing agent PEG, 
a particle size of 640 nm was observed with a high zeta potential of ca. 32 mV (Figure 
6.6). When nitroPBA-PEG was added to stabilize the particle, the diameter reduced to ca. 
130 nm with a negative surface charge of ca. -4 mV. This negative charge is a result of 
the binding between boronic acid and diols. When 0.25 mol% Herceptin conjugated 
nitroPBA-PEG was introduced, interestingly, the particle size reduced further to 82 nm 
while the zeta potential remained similar. 
 
 
Figure 6.6 Zeta potential and effective hydrodynamic diameter of MAD-4/siRNA 
nanoparticles stabilized by different PEG chains. Formulated at charge ratio of 3 (+/-), 
zeta potential (bar), effective diameter (scatter). 
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Figure 6.7 provides the salt stability data for MAD-4/siRNA nanoparticles with 
various PEG groups attached. Without the presence of stabilizing agent PEG, the 
particles aggregated. When nitroPBA-PEG was present, particles remained stable in salt 
conditions. 
 
Figure 6.7 Salt stability of MAD-4/siRNA nanoparticles stabilized with no PEG, 
nitroPBA-PEG and 0.25 mol% Herceptin-PEG-nitroPBA. Formulated at charge ratio 3 
(+/-), 10x PBS was added at time 5 min such that the resulting solution was in 1x PBS. 
 
6.4.4 In Vivo Characterization 
Based on the promising in vitro results, the best nanoparticle formulation 
composed of siRNA condensed by MAD-4 and stabilized with nitroPBA-PEG at charge 
ratio of 3 (+/-) proceeded to animal pharmacokinetic evaluation. BALB/c mice were 
injected with particle formulations containing 20% siCy3 (fluorescently labeled siRNA) 
via tail vein injection and blood was collected from saphenous vein at various time points. 
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Figure 6.8 shows the pharmacokinetic data for MAD-4/siRNA nanoparticles stabilized 
with nitroPBA-PEG. It can be seen that at 2 min post injection, there was significantly 
more siCy3 remaining for MAD-4/siRNA nanoparticles than that for CDP/siRNA 
nanoparticles (CALAA-01). However, by 7 min both groups show similar fast in vivo 
clearance.  
 
 
Figure 6.8 Pharmacokinetics of MAD-4/siRNA nanoparticles stabilized with nitroPBA-
PEG in BALB/c mice, compared with that of CALAA-01 (CDP/siRNA nanoparticles 
stabilized with AD-PEG). Formulated with 20% siCy3, charge ratio 3 (+/-), 5 mg 
siRNA/kg mouse injection, dashed lines join data for each individual mouse. 
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6.5 Conclusions  
An example for the use of boronic acid-diol complexation in the targeted delivery 
of siRNA via nanoscaled vehicles was presented. A copolymer of mucic acid and 
dimethylsuberimidate (DMS), named MAD, was synthesized and used to condense the 
anionic siRNA into nanoparticles. The condensed nanoparticles were stabilized by 
placing a PEG layer onto the particle surface using boronic acid-diol complexation where 
boronic acid PEG (BA-PEG) form reversible covalent bonding with vicinal diol groups 
on the MAD backbone. Targeting was achieved by conjugating the distal end of the BA-
PEG with a targeting agent, in this case, a Herceptin antibody. MAD/siRNA 
nanoparticles were found to effectively enter cells by transfection studies and show low 
cellular toxicity. It was found by gel electrophoresis studies that charge ratios of 1.5 (+/-) 
for MAD-2 and MAD-4 were sufficient to encapsulate all siRNA. MAD/siRNA 
nanoparticles stabilized with nitroPBA-PEG were formulated with a diameter of ca. 130 
nm and a surface charge of ca. -4 mV. Pharmacokinetic studies in mice demonstrate 
improved circulation compared to CALAA-01.  
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Chapter VII 
Future Directions and Recommendations  
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  In the previous chapters, it has been shown that boronic acid-diol complexation 
can be used in the targeted delivery of both camptothecin (CPT) and siRNA. Thus the 
purpose of this thesis has been fulfilled. Yet, as with all scientific endeavors, the more we 
learn about a system, the more question arises. In the following, I will provide some 
future directions and recommendations for the targeted, polymeric delivery of CPT and 
siRNA via boronic acid-diol complexation.  
  First, this delivery platform utilizes boronic acid-diol complexation for targeting 
(MAP-CPT and MAD/siRNA) and stabilization purposes (MAD/siRNA) by tethering 
PEG modified at the distal end with a boronic acid and complexing this with diol-
containing groups on the surface of the nanoparticles. However, there are sugars, 
including glucose present in vivo that could compete for binding with boronic acids. This 
could potentially lead to PEG chains falling off of the particle and thus reduce the 
targeting capability and/or stability of the nanoparticles. It is proposed that studies in 
quantifying the amount of boronic acid that remains on the surface of the nanoparticles as 
a function of time as they circulate in vivo be conducted. If boronic acids are found to be 
falling off of the particles and are binding to unspecific sugar groups, effects of this 
behavior on the delivery system and in the host should be investigated.   
  To increase the binding constant of boronic acid to diols, a series of 
phenylboronic acids (PBA) with electron withdrawing groups on the phenyl ring has been 
synthesized. This effectively increased the binding constant between MAP and PBA by 
over 70 times. Another way of increasing the binding constant is by introducing 
multivalent interactions. Nanoparticles possessing multiple targeting agents on its surface 
and can multivalently bind to receptors have been shown to have significantly lower 
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dissociation constants, KD (1, 2).  In Chapter V, we examined the effect of multivalency 
in the PEG stabilization of CDP/siRNA nanoparticles. It was found that CDP/siRNA 
nanoparticles stabilized with multivalently attached PEG, AD2-PEG or AD3-PEG, 
demonstrated enhanced stability in both in vitro and in vivo conditions. Therefore, 
another method of increasing the binding constant between boronic acids and diols is to 
multivalently attach boronic acid groups, for instance, (PBA)2-PEG onto the surface of 
the nanoparticles. This would result in potentially less off targeting affect due to PEG 
falling off of the nanoparticle in the MAP-CPT and MAD/siRNA systems; and increasing 
the nanoparticle stability in the MAD/siRNA system.   
  The design of our delivery platform is modular such that in theory any targeting 
agent can be placed on the surface of the nanoparticles. Those include whole antibodies 
other than Herceptin, antibody fragments such as F(ab’)2 and Sc-Fv, proteins including 
human transferrin, and peptides. MAP can be conjugated to other small molecule 
hydrophobic drugs. As well, sugars other than mucic acid can be used in the synthesis of 
the hydrophilic polymer for small hydrophobic drug delivery and in the synthesis of 
cationic siRNA condensing polymer.  
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